INVASIVE MENINGOCOCCAL DISEASE
IN MARICOPA COUNTY
January 1, 2000-June 30, 2006*

Office of Epidemiology and Vital Statistics
Maricopa County Department of Public Health
December 2006

*This report is excerpted from Invasive Meningococcal Disease in Maricopa County 2000-2006, a
University of Arizona Masters of Public Health Internship Project completed 11/24/06 by
Natalia Wilson, MD. For questions please contact Natalia Wilson at nataliaann6@cox.net or
Vjollca Berisha at vjollcaberisha@mail.maricopa.gov

TABLE OF CONTENTS
Overview of Invasive Meningococcal Disease……………………………
Epidemiology in the United States………………………………………….
Surveillance in the United States……………………………………………
Treatment………………………………………………………………………….
Prevention…………………………………………………………………………
Prevention Mandates for US Colleges and Universities………………..
Surveillance in Maricopa County…………………………………………….
Epidemiologic Trends in Maricopa County 2000-2006…………………
Overall……………………………………………………………………………………………..
Seasonality……………………………………………………………………………………….
Distribution by Serogroup………………………………………………………………….
Distribution by Age……………………………………………………………………………
Distribution by Age and Serogroup……………………………………………………..
Distribution by Race/Ethnicity…………………………………………………………….
Distribution by Race/Ethnicity and Serogroup……………………………………..
Distribution by Gender………………………………………………………………………
Distribution by Syndrome………………………………………………………………….
Geographic Distribution…………………………………………………………………….
Reporting & Investigation in Maricopa County 2005-2006…………
Conclusions………………………………………………………………………
Areas of Future Study & Action……………………………………………..
Appendix………………………………………………………………………….
A. Cases & Deaths of IMD in MC by Syndrome, 2000-2006, per year…..
B. Cases & Deaths of IMD in MC by Race/Ethnicity, 2000-2006,
per year…………………………………………………………………………………..
C. Cases & Deaths of IMD in MC by Gender, 2000-2006, per year……..
D. Cases & Deaths of IMD in MC by Age, 2000-2006, per year……………
E. Cases & Deaths of IMD in MC by Serogroup, 2000-2006, per year….
F. IMD in MC by Serogroup and Age, 2000-2006, per year………………….
G. IMD in MC by Serogroup and Race/Ethnicity, 2000-2006, per year…..
H. IMD in MC by Month of Onset, 2000-2006…………………………………….
I. IMD in MC by Serogroup, 2000-2006…………………………………………….
J. IMD in MC, CFR by Syndrome, Race/Ethnicity, Gender, Age, &
Serogroup………………………………………………………………………………….
K. Rate of IMD in the US & MC, 1983-2006………………………………………
L. Population Estimates for MC, 1983-2006……………………………………….
M. US Population Estimates, 1983-2005…………………………………………….
References………………………………………………………………………..

2

3
4
6
6
7
8
8
9
9
11
12
14
15
18
19
19
20
20
22
24
24
26
27
29
32
34
38
41
50
58
59
60
62
63
65
66

Overview of Invasive Meningococcal Disease

Neisseria meningitidis or meningococcus is a gram negative diplococcus. At

least 13 serogroups are known. The most common of these, which cause the
majority of clinical disease, are A, B, C, Y, and W-135.5,6 Humans are the only
host of N.meningitidis.7 Transmission occurs via contact with large aerosol
droplets or contact with respiratory tract secretions. Examples of contact
include kissing, sharing drinks or cigarettes, mouth-to-mouth resuscitation, and
intubation.6
A carrier state occurs in 10% or more of the population.8 This may increase
to 60-80% in closed populations.9 Carriers are most frequently colonized in the
nasopharynx with low or non-pathogenic strains of N. meningitidis or a related
non-pathogenic bacteria, N. lactamica.5,8 By age 30, the majority of the
population has had 10 different episodes of carriage.8 Carriage is an immuneinducing event. Cross-reactivity of antibodies occurs.10 By adulthood, the
majority of people have formed antibodies to A, B, C, Y, and W-135.11 Carriage
is highest in adolescents and lowest in young children.8 Despite this relatively
high carrier state, less than 1% of colonized organisms invade.12
Clinical syndromes caused by N. meningitidis include septicemia, meningitis,
bacteremia, pneumonia, and other infections of normally sterile body fluid,
such as septic arthritis, conjunctivitis, and pericarditis.5 In septicemia, patients
often present with hypotension, diffuse petechiae, and may develop
disseminated intravascular coagulation and purpura fulminans. In meningitis,
the organism crosses the blood-brain barrier. This occurs in 50% of the cases
and occurs 24-48 hours after the bacteria invades the bloodstream.9,12 Cases of
bacteremia often present with non-specific symptoms and meningococcus may
not be suspected.2 Pneumonia occurs in up to 15% of the cases.12 The
incubation period of the organism is generally 2-4 days but ranges from 1-10
days. A patient remains infectious as long as N. meningitidis remains in the
nasopharynx and until 24 hours after receiving appropriate antibiotics.13
High risk groups include:
• College freshmen living in dormitories
• Military recruits
• Microbiologists routinely exposed to N. meningitidis
• Those with terminal complement component deficiencies
• Those with functional/anatomic asplenia
• Travelers to hyperendemic or epidemic areas. Examples include
Sub-Saharan Africa, “the meningitis belt” and Saudi Arabia during
the pilgrimage to Mecca.1,10
Risk factors for disease include antecedent viral infection, crowding, chronic
disease, including hepatic disease, multiple myeloma, and systemic lupus
erythematous, and active and passive smoking. Black race and lower
socioeconomic status are felt to be risk markers for IMD.1,10

Epidemiology in the United States
Overall
Approximately 1,400-2,800 cases/year occur in the US. The rate of disease is
0.5-1.1/100,000 population.1 This range reflects the cyclical incidence of the
disease.14 98% of cases are sporadic. Outbreaks are uncommon.11 CFR is high,
10-14%, and may be as high as 20% in the adolescent population.1,15 Morbidity
in survivors occurs in 11-19% and includes limb loss, neurologic disability, and
hearing loss.1 IMD follows a seasonal pattern with the majority of cases in the
winter and early spring months.16

Distribution by Serogroup

In the US, serogroups B, C, and Y each cause about 1/3rd of cases. In the
infant population, ≥50% of cases is caused by serogroup B. For ages ≥ 11, 75%
is caused by C, Y, and W-135, vaccine-preventable serogroups.1 A higher
proportion of serogroup Y IMD occurs in the elderly.11 Serogroup A rarely causes
disease in the US.5
Internationally, serogroup A is significant in Africa and Asia. Serogroup B is
significant in Europe, South America, New Zealand, and Australia.9
Antigenic shift provides a possible explanation for the change in serogroup
distribution over time. Dramatic changes were noticed in the 1990’s. Cases
caused by serogroup Y increased from 2% in 1989-1991 to 37% in 1997-2002.
Additionally, disease rate increased in the 15-24 year old population with
approximately 50% caused by serogroup C. In antigenic shift, the bacteria
genetically changes so that a new virulent strain of the serogroup forms and
evades established host immunity.14

Distribution by Age
As can be seen in FIGURE 1, IMD has two main peaks by age. The greatest
rate of IMD occurs in the <1year old population. A second peak occurs in late
adolescence.15 Some possible explanations for the <1 year old peak are the loss
of maternal antibody protection at 3 months and the low carriage state. For the
late adolescent population, crowding, smoking, and the high carriage state
contribute to the peak in incidence. The carrier state provides exposure to
N.meningitidis and antibody development, but also provides exposure to virulent
strains and the risk of invasive disease.5,8

4

FIGURE 1: Rate of Meningococcal Disease by age-US, 1991-2002

Centers for Disease Prevention and Control. Prevention and Control of Meningococcal Disease:
Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2005;54(RR-7).

Although the greatest rate of disease is in the <1 year old population, the
greatest burden of disease (% of cases) is in the 25-64 year old population as
can be seen in FIGURE 2.15

FIGURE 2: Burden of disease (percentage of cases) and rates of
invasive meningococcal disease (all serogroups) in the United States,
1991-2002, according to age (CDC, Active Bacterial Core surveillance)
Committee on Infectious Diseases, Pediatrics 2005;116:496-505

5

Distribution by Race/Ethnicity
Blacks are at a higher risk of IMD although this is felt to be a risk marker.
(due to environmental factors rather than a genetic predisposition to developing
the disease.)1

Distribution by Gender

Males account for 51-55% of cases.9,17

Distribution by Syndrome
Meningitis, defined as meningitis with or without meningococcemia is more
common than bacteremia alone. The death rate is higher with
meningococcemia.17-19

Surveillance in the United States
Surveillance on a national level is accomplished in two ways. States send
information to the CDC once a week via the National Electronic
Telecommunications System for Surveillance (NETSS) on nationally reportable
diseases which includes IMD. Provisional data is published weekly in MMWR. At
the end of the year, the compiled data is corrected and finalized. This report is
published in MMWR as a Summary of Notifiable Diseases for that year. A
limitation of this sytem is that reporting is voluntary.20 Active Bacterial Core
surveillance (ABCs) is an active surveillance system for 6 pathogens including N.
meningitidis. There are 10 sites in the US representing a population of over 38
million persons. For ABCs cases, additional demographic information is obtained
on cases, additional laboratory studies are performed on samples, isolates are
sent to the CDC for additional testing, and laboratories are both contacted and
audited regularly.21

Treatment

Intravenous (IV) Penicillin G is the treatment of choice.9 Alternatives are IV
Ceftriaxone and Ampicillin. IV Chloramphenicol is a choice for penicillin allergic
patients.13 Except for the third-generation cephalosporins, the IV treatment
options do not eradicate nasopharyngeal carriage. Patients not receiving an IV
third-generation cephalosporin for the acute disease need one of the
chemoprophylactic antibiotics prior to hospital discharge to eradicate
nasopharyngeal carriage.24 Antibiotic resistance to Penicillin has not been a
problem in the US with N. meningitidis.9

6

Prevention
A. Vaccination
Currently there are two meningococcal vaccines available in the US, the
meningococcal polysaccharide vaccine (MPSV4 or Menomune) and the
meningococcal conjugate vaccine (MCV4 or Menactra). Both of these vaccines
are tetravalent and contain antigens to serogroups A,C,Y, and W-135. There is
no serogroup B coverage in these vaccines.11
The meningococcal polysaccharide vaccine was licensed in 1981 for use in
those ≥2 years of age. This vaccine has been used in all military recruits since
1982. Limitations of this vaccine include a short duration of protection, booster
may lead to a diminished antibody response, lack of interruption of the carrier
state, and lack of herd immunity.1,11
The meningococcal conjugate vaccine was licensed in January 2005 for use in
those 11-55 years of age. The advantages of this vaccine include a longer
duration of protection and booster leads to a rise in antibodies. Assumed
advantages, based on experience with other conjugate vaccines such as that for
H.influenza and S.pneumoniae, include a reduction in the carrier state and
development of herd immunity.
In the US, the Advisory Committee on Immunization Practices of the CDC
has recommended routine vaccination with the meningococcal conjugate vaccine
for 11-12 year olds at their pre-adolescent physician visit; catch-up at age 15 if
vaccine not yet received; and to those in high risks groups, which includes
entering college students who plan to live in dormitories.1 Groups that have
endorsed these recommendations include the American Academy of Pediatrics
and the American Academy of Family Physicians.15,32

B. Chemoprophylaxis
Chemoprophylaxis is an important component of prevention. Contacts of
IMD cases who should receive prophylaxis include household contacts, child-care
center contacts, and those who have had prolonged and/or intimate contact with
the patient.1 Generally, school and work contacts are not included unless the
contact has been close. Administration of chemoprophylaxis is ideal within 24
hours. Benefit is still achieved up to 2 weeks, however, the benefit decreases as
time elapses from the exposure. After 2 weeks, the benefit is not appreciable
and hence is not recommended. The current choices for prophylaxis are
• Rifampin for adults and children, oral dose twice a day for 2 days
• Ciprofloxacin for adults, one time oral dose
•
Ceftriaxone for adults and children, one time intramuscular dose 11

7

Prevention Mandates for US Colleges and Universities
As shown in FIGURE 3, mandates for meningococcal prevention for college
students differ from state to state. 11 states currently require proof of
vaccination or waiver for their colleges and universities. 24 states require
education. The remaining 15, which includes Arizona, do not have
requirements.33
FIGURE 3

Source=Immunization Action Coalition (2006). Available from http://www.immunize.org/laws/meninmap.pdf

Surveillance in Maricopa County
Reporting is required in Arizona under the Arizona Administrative Code.
Reporting requirements differ by reporting group. For health care providers, a
report must be submitted to the local health department within 24 hours for a
case or suspect case. For laboratories, a report on a positive lab test must be
submitted within 24 hours to the Arizona Department of Health Services and
isolates must be submitted to the Arizona State Public Health Laboratory.
Violation of this reporting is a Class III Misdemeanor.22
The case definition of a confirmed case of IMD is a clinically compatible case
with culture confirmation of N. meningitidis from a normally sterile site. A

8

probable case is a clinically compatible case with a positive PCR or positive N.
meningitidis antigen. A suspect case is presence of purpura fulminans without a

positive blood culture or clinical compatibility with gram negative diplococci on
gram stain of a sample from a normally sterile site. 23
Data from the Communicable Disease Report form (CDR) submitted to
MCDPH is maintained in an electronic CDR database. Case investigation is
performed by a community health nurse investigator using the National Bacterial
Meningitis and Bacteremia Case Report form (long form). The data from the long
forms is transferred to an Excel spreadsheet and maintained electronically. This
data is available from G:\EPI\New Surveillance\Communicable Diseases\Specific
Diseases\Bacterial meningitis\Forms

Epidemiologic Trends in Maricopa County 2000-2006
Overall
During 1/1/2000-6/30/2006, 113 confirmed and probable in-county cases of
IMD were reported to MCDPH. 12 deaths occurred in this group. (See TABLE 1)

# of
Cases

TABLE 1, Invasive Meningococcal Disease in Maricopa County
2000-2006*
2000
2001
2002
2003
2004
2005
2006
28
13
20
17
11
19
5

Total
113

0.90

0.41

0.61

0.50

0.31

0.52

# of
Deaths

3

0

5

1

0

1

2

12

Case
Fatality
Rate

11%

0%

25%

6%

0%

5%

40%

11%

Rate

*Year 2006 through 6/30/2006
Rates per 100,000 population US Census estimates

0.22†

†Annualized as of 6/30/2006

Rate of disease was at a high of 0.90 in 2000 and slowly trended down over
time to a low in 2006 of 0.22 (annualized). Median rate was 0.5. Annualized
average rate was 0.47. At no time during the study period was the rate
9

≥ 1/100,000 population. The overall case-fatality rate was 11% which was
similar to that previously discussed from the literature.
FIGURE 3 provides an overall look at the rate of IMD in MC from 1983-2006.
An outbreak occurred in 1993.

FIGURE 3, Invasive Meningococcal Disease in Maricopa County, Rates
by Year on Onset, 1983-2006*

R a te

3.00
2.00
1.00
0.00

83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 00 01 02 03 04 05 06

Rate MC 1.02 0.52 0.871.00 1.00 0.78 0.570.38 0.73 0.76 2.671.82 1.78 1.11 1.000.86 1.12 0.90 0.410.61 0.50 0.31 0.520.22
Year of Onset
*Year 2006 annualized as of 6/30/2006
Rates per 100,000 population US Census estimates

All MC data from MCDPH, Office of
Epidemiology

FIGURE 4 shows the rates of IMD in the US and MC from 1983-2006. The
rate in MC from 2000-2006 was similar to the US rate during this same time
period. In both cases, the rate slowly trended down over time and was
<1/100,000 population.

10

FIGURE 4, Invasive Meningococcal Disease in the US and Maricopa
County, Rates by Year of Onset 2000-2006*
3.00
2.50

R a te

2.00
Rate MC

1.50

Rate US

1.00
0.50
0.00

83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 00 01 02 03 04 05 06

Rate MC 1.02 0.52 0.87 1.00 1.00 0.78 0.57 0.38 0.73 0.76 2.67 1.82 1.78 1.11 1.00 0.86 1.12 0.90 0.41 0.61 0.50 0.31 0.52 0.22
Rate US 1.17 1.16 1.04 1.08 1.21 1.21 1.10 0.98 0.84 0.84 1.02 1.11 1.23 1.30 1.24 1.01 0.92 0.80 0.82 0.63 0.60 0.46 0.37
Year of Onset

*Year 2006 annualized as of 6/30/2006
All MC data from MCDPH. Office of
Rates per 100,000 population US Census estimates
Epidemiology
Raw numbers for US rate calculation obtained from CDC. Summary of Notifiable Diseases, US, 2000-2004.
MMWR 2000;49(53); MMWR 2001;50(53);MMWR 2002;51(53);MMWR 2003;52(54);MMWR2004;53(53)2004
& CDC. Notifiable Diseases/Deaths in Selected Cities Weekly Information. MMWR 2006;54(52);1320-1330

Seasonality
The distribution of cases by month of onset in MC followed a seasonal pattern
similar to what was discussed earlier from the literature. A higher percentage of
cases were seen in the winter and early spring months.(See FIGURE 5)

n=
15
n=
Ap 17
ril
n=
4
M
ay
n=
7
Ju
ne
n=
6
Ju
ly
n=
Au 4
g
n=
4
Se
pt
n=
2
O
ct
n
No =9
v
n=
De 14
c
n=
9
ar
ch

M

Fe
b

n=
17

18%
16%
14%
12%
10%
8%
6%
4%
2%
0%

Ja
n

Percentage of Cases

FIGURE 5, Invasive Meningococcal Disease in Maricopa County,
Percentage Distribution by Month of Onset 2000-2005

Month of Onset

11

Distribution by Serogroup
The proportions of IMD cases by serogroup in MC differed from that reported
in the literature for the US.( See FIGURE 6) Unlike the US where serogroups B,C,
and Y each cause 1/3rd of cases, in MC B caused 26%; C caused 18%; and Y
caused 20%. 15% of MC cases were unknowns and 17% were Not Groupable.
Unknowns were samples that were not sent to the AZ State Lab for serogrouping
or cultures that did not grow because the patient received antibiotics prior to
obtaining the cultures. Not Groupables are capsule-deficient samples that cannot
be serogrouped due to their lack of capsule. Not Groupable samples that cause
disease are either genetically B, C, or Y but capsule-deficient or another
unidentifiable serogroup that is capsule-deficient.34 The effect of these two
groups on the MC data is unclear.

FIGURE 6, Invasive Meningococcal Disease in Maricopa County by
Serogroup, 2000-2005

15%
26%
Group B, n=29
Group C, n=19

17%

Group Y, n=22
Others, n=4
Not Groupable, n=18

4%

18%
20%

Others=Serogroups A & W-13

12

Unknow n, n=16

Comparison of the proportion of IMD cases by serogroup in MC to the US per
ABCs data showed MC with a lower proportion of serogroup B cases and a higher
proportion of Other cases, those due to W-135 or Not Groupables. (See FIGURES
7a & 7b) Only 3 cases of W-135 occurred in MC between 2000-2005, so the
Other category in MC was mainly Not Groupables.
FIGURES 7a & 7b, Invasive Meningococcal Disease in the US and
Maricopa County by Serogroup, 2000-2005
2000-2005 US

14%

41%

Group B, n=521
Group C, n=277

24%

Group Y, n=315
Other n=177

21%

2000-2005 MC

24%
32%
Group B, n=34
Group C, n=22
Group Y, n=26
Other n=25
24%
20%

US data per Active Bacterial Core Surveillance (ABCs) Report Emerging Infections Program Network
Neisseria meningitidis, 2000-2005-provisional
Unknowns diistributed among knowns
Other=Serogroup W-135 & Not Groupables

13

Most notable when looking at proportion of serogroup for IMD cases in MC
was the consistency of the proportion of vaccine-preventable cases over time.
Proportion of vaccine-preventable disease was approximately 40-45% each year
except in 2001. Of note also is that the proportion of unknown cases seemed to
be increasing. (See FIGURE 8)
FIGURE 8, Invasive Meningococcal Disease in Maricopa County by
Serogroup, 2000-2005
Proportion of Cases

100%
80%
Unknow n n=13

60%

Not Groupable n=18
Vaccine Preventable n=45

40%

Group B n=29

20%
0%
2000 2001 2002 2003 2004 2005
n=28 n=13 n=20 n=17 n=11 n=19
Year

Vaccine Preventable=Groups A,C,Y,W-135

Distribution by Age
Most notable in the distribution of IMD by age in MC was the rate for the 0-4
year old population. This rate trended down over time. (See FIGURE 9). By
2004-2005, all age groups had fairly similar rates of disease.
FIGURE 9, Invasive Meningococcal Disease in Maricopa County by Age,
2000-2005
5.00
Rate

4.00
0-4years, n=34

3.00

5-9 years, n=7

2.00

10-24 years, n=30

1.00

25-64 years, n=26
65+ years, n=11

Year
Rates per 100,000 US Census population estimates

14

20
05

20
04

20
03

20
02

20
01

20
00

0.00

Comparison of the distribution of IMD for the 0-4 year old population
between MC and the US, using ABCs data (FIGURE 10), showed that both were
trending down over time. By 2004, however, the rate in the 0-4 year old
population in MC seemed to be lower than that in the US.
Figure 10, Invasive Meningococcal Disease in US and Maricopa County,
Age 0-4 Years, 2000-2005
5.00

Rate

4.00
0-4 years MC

3.00

0-4 years US

2.00
1.00
0.00
2000 2001 2002 2003 2004 2005
Year

Rates per 100,000 US Census population estimates.
Raw numbers for US rate calculation obtained from CDC. Summary of Notifiable Diseases, US, 2000-2004.
MMWR 2000;49(53); MMWR 2001;50(53);MMWR 2002;51(53);MMWR 2003;52(54);MMWR
2004;53(53)2004

Distribution by Age and Serogroup
Comparison of the serogroup distribution in the <1 year old populations in
MC to that in the US per ABCs data (See FIGURES 11a & 11b), showed a lower
proportion of serogroup B disease and a higher proportion of Other disease in
MC. No cases of W-135 occurred in the <1 year old population in MC during
2000-2005 so the Other category in MC was entirely Not Groupables. The
proportion of serogroup B cases in the US data seemed consistent with that
discussed in the literature, ≥50%. MC’s proportion was lower than this at 37%.
The highest proportion of cases in MC in the <1 year old population was Not
Groupables.

15

FIGURE 11a & 11b, Invasive Meningococcal Disease in the US &
Maricopa County, Age < 1 year by Serogroup,
2000-2005

2000-2005 US
6%
14%
Group B n=111
Group Y n=30
17%

63%

Other n=25
Group C n=11

2000-2005 MC

37%
42%

Group B n=7
Group Y n=4
Other n=8

21%
US data per Active Bacterial Core Surveillance (ABCs) Report Emerging Infections Program Network
Neisseria meningitidis, 2000-2005-provisional
Unknowns distributed among knowns
Other=W-135 & Not Groupables

IMD in the <1 year old population in MC has decreased over time. (See
FIGURE 12) As discussed earlier, per the literature the <1 year old population
has the highest overall rate of IMD. In MC, there have no cases in this age group
since 2004 and no cases of serogroup B disease since 2002.

16

Proportion of Cases

FIGURE 12, Invasive Meningococcal Disease in Maricopa County,
Age < 1 year by Serogroup, 2000-2005
100%
90%
80%
70%
60%

Unknown, n=3
Not Groupable, n=7

50%
40%
30%
20%
10%
0%

Group Y, n=3
Group B, n=6

2000

2001

2002 2003

2004

2005

Year

Evaluation of distribution of IMD by age and serogroup in MC showed that
the proportion of C, Y, and W-135 was less than the 75% quoted in the literature
for those ≥11 years. (See FIGURE 13) The effect the Unknown and Not
Groupable categories have on this is unclear. In the elderly, Y caused the
greatest proportion of cases which is consistent with that mentioned earlier from
the literature.
FIGURE 13, Distribution of Invasive Meningococcal Disease in Maricopa
County by Age & Serogroup, 2000-2005

Proportion of Cases

100%
80%

Unknow n n=16
Not Grp n=18

60%

Other n=7
Group Y n=22

40%

GroupC n=19
Group B n=29

20%
0%
0-4yrs

5-9yrs 10-24yrs 25-64yrs 65+yrs
Age

17

The proportion of vaccine-preventable disease in MC was greatest in the 1024 year old and 25-64 year old populations. (See FIGURE 14)
FIGURE 14, Vaccine-Preventable* Invasive Meningococcal Disease in
Maricopa County by Age 2000-2005

16%

18%
0-4yrs, n=8
5-9yrs, n=3

7%

10-24yrs, n=13
25-64yrs, n=14

30%

65+yrs, n=7
29%

*Vaccine Preventable=A,C,Y,W-135

Distribution by Race/Ethnicity
The rate of IMD in the Hispanic population in MC trended down during the
study period. (See FIGURE 15) By 2004-2005, the rates in all 3 race/ethnicity
categories were very similar.
FIGURE 15, Invasive Meningococcal Disease in Maricopa County by
Race/Ethnicity, 2000-2005

2.5
2
Rate

White, n=56

1.5

Hispanic, n=42
Other, n=10

1
0.5
0
2000

2001

2002

2003

2004

2005

Year
Rates per 100,000 US Census population estimates
Other includes Black, American Indian,Alaskan Native, Asian/Pacific Islander

18

Distribution by Race/Ethnicity and Serogroup
During the study period, the non-white populations had higher rates for
serogroup B disease and the Hispanic population had the highest rate for
vaccine-preventable disease. (See FIGURE 16)
FIGURE 16, Invasive Meningococcal Disease in Maricopa County by
Race/Ethnicity and Serogroup,
2000-2005
0.35
0.30

Rate

0.25
White, n=56

0.20

Hispanic, n=42

0.15

Other, n=10

0.10
0.05
0.00
Group B n=29

Vaccine
Preventable
n=45

Not Groupable
n=18

Unknown n=16

Serogroup
Rates per 100,000 US population estimates
Other includes Black, Native American/Alaskan Native, Asian/Pacific Islander

Distribution by Gender
Rates of IMD in MC for male and females during the study years were very
similar. (See FIGURE 17)

Rate

FIGURE 17, Invasive Meningococcal Disease in Maricopa County by
Gender, 2000-2005
1.00
0.90
0.80
0.70
0.60
0.50
0.40
0.30
0.20
0.10
0.00

Male, n=57
Female, n=56

2000

2001

2002

2003

Year

19

2004

2005

Distribution by Syndrome
In MC, the highest proportion of IMD by syndrome was due to cases of
bacteremia alone, closely followed by meningitis. A very low proportion of cases
was caused by other syndromes. (See FIGURE 18) In the US ABCs data and in
the literature, the highest proportion of cases was due to meningitis.

FIGURE 18, Invasive Meningococcal Disease in Maricopa County by
Syndrome, 2000-2005

Proportion of Cases

60%
50%
40%
US

30%

Maricopa County

20%
10%
0%
Bacteremia

Meningitis

Other

Syndrome
US data per Active Bacterial Core Surveillance (ABCs) Report Emerging Infections Program Network
Neisseria meningitidis, 2000-2005-provisional
Meningitis=meningitis +/-meningococcemia

Geographic Distribution
No apparent clusters were seen for IMD in MC during the study period. (See
MAP 1) For 2002, 6 cases did occur in census tracts of relatively close proximity
along a north to south corridor in Phoenix.

20

MAP 1: Invasive Meningococcal Disease in Maricopa County
by Census Tracts 2000-2006

14/113 cases (12%) not geocoded.
Generated using ArcMap GIS software.

21

Statistical Analysis
Limited statistical analysis was performed on the data. Using SPSS, a logistic
regression model was used to test for any statistically significant relationship
between age, sex, serogroup. or syndrome and outcome; and between
serogroup and age. No statistically significant associations were found.

Reporting and Investigation in Maricopa County
2005-2006
A subset of cases reported to MCDPH from 1/1/2005-6/30/2006 was analyzed.
27 cases occurred during this period. In approximately 50% of cases, IMD cases
were reported to MCDPH 1-2 days after cultures were obtained. In the other
50% of cases, report was made ≥3 days after cultures were obtained. (See
FIGURE 19) As discussed earlier, health care providers are required to report a
suspect or confirmed case of IMD within 24 hours.
FIGURE 19, Time to Report Case* to Maricopa County Department of
Public Health, 1/1/2005-6/30/2006

Percentage of Case

35%
30%
25%
20%
15%
10%
5%
0%
≤1 n=8

2 n=6

3-5 n=9

6-7 n=2

>7 n=2

Days to Report
*Case=confirmed & probable, Maricopa County or out of state
Time to report case=time from date of 1st culture to date of report

In 26 out of 27 cases in the subset of data analyzed, investigation at MCDPH
was done on the same day as the report received. In one case, no information
was provided in the record as to the date of investigation. (See FIGURE 20)

22

FIGURE 20, Time to Start Investigation at Maricopa County
Department of Public Health after Report Received,
1/1/2005-6/30/2006

Percentage of Cases

100%
80%
60%
40%
20%
0%
Same day n=26

Unknow n n=1

Days to Start Investigation

In the majority of cases, prophylaxis of contacts was done. (See FIGURE 21)
In seven cases the record was unclear as to whether prophylaxis was done or
not.
FIGURE 21, Prophylaxis of Cases, 1/1/2005-6/30/2006

Percentage of Cases

80%
70%
60%
50%
40%
30%
20%
10%
0%
Done n=18

Not done n=2
Prophylaxis

23

Unclear n=7

Conclusions
This study provides baseline epidemiologic trends of IMD in MC. The trends of
particular interest include
1. The lower proportion of serogroup B cases
2. The higher proportion of Not Groupable cases
3. The declining rate in the 0-4 year old population
4. The lack of any cases in the <1 year old population since 2004
5. The lack of any B cases in the <1 year old population since 2002
6. The higher proportion of Bacteremia alone cases
7. The sizeable proportion of vaccine-preventable disease
8. The highest rate of vaccine-preventable disease in the Hispanic population
This study also provides useful information for MCDPH, Office of
Epidemiology on reporting, investigating, and data completeness. Reporting of
cases of IMD to MCDPH occurred ≥ 3 days in about 50% of the cases, despite a
24 hour reporting mandate for cases or suspect cases.
Data on IMD in MC can be analyzed on a yearly basis using this study as a
model. Future analyses can reassess the epidemiologic trends noted in this study
and assess the effect of routine meningococcal vaccination in MC. Reassessment
of the distribution of vaccine preventable disease by age will be important. If the
conjugate vaccine interrupts the carrier state and if herd immunity is elicited, the
proportion of vaccine preventable disease should decrease in both the
immunized and not immunized populations. If immunity lasts long, over time
older age groups should show a lower proportion of vaccine-preventable disease.

Areas of Future Study & Action
Areas of further investigation and action should include
1. The Not Groupable serogroup category.
• Is there a lab cause for the higher proportion of Not Groupable
cases in MC compared to the US ABCs data?
• Is an unidentified serogroup causing disease in MC?
• Could the AZ State Lab collaborate with the CDC to evaluate this?
2. The higher rate of vaccine preventable disease in the Hispanic population.
• Would GIS mapping of vaccine preventable disease in MC by
race/ethnicity and serogroup provide useful information?
• Are the cases grouped in similar areas where vaccination could be
targeted?
3. Late reporting of cases
• Send a letter to health care providers in MC about the reporting
requirements, the conjugate vaccine, and the importance of
reporting to achieve early prophylaxis and thorough documentation
of cases.
24

•

Send a letter to laboratories in MC about the reporting
requirements and reinforce the importance of sending isolates to
the AZ State Lab for serogrouping so that the epidemiology of IMD
in MC can be accurately understood.
• A possible future internship project could be analysis of timeliness
of reporting to MCDPH for various diseases, determination of
barriers to timely reporting, and determination of methods for
improvement.
4. Colleges and Universities in MC
• Contact in reference to meningococcal vaccination policies for
entering students
5. Documentation of meningococcal vaccination status
• Routinely obtain this information as part of the case investigation
• Obtain updated CDC National Bacterial Meningitis and Bacteremia
Case Report form with fields for vaccination information when
available (currently in draft stage per CDC)
6. CDC
• Follow-up with the CDC to discuss this report

25

APPENDIX

26

A. Cases & Deaths of Invasive Meningococcal Disease(IMD) in
Maricopa County(MC) by Syndrome, 2000-2006, per year
TABLE 1-Cases & Deaths of IMD in MC by Syndrome in 2000
Cases
#
%
Rate*
Syndrome
Meningitis
7
25%
0.23
Bacteremia
17
61%
0.55
Both
4
14%
0.13
Other
0
0%
0.00
Total
28
100%
0.90
*†per 100000 population, estimates per US Census

Deaths
Rate†
0%
0.00
100%
0.10
0%
0.00
0%
0.00
100%
0.10

#

%

0
3
0
0
3

CFR
0%
11%
0%
0%
11%

TABLE 1-Cases & Deaths of IMD in MC by Syndrome in 2001
Cases
#
%
Rate*
Syndrome
Meningitis
3
23%
0.09
Bacteremia
6
46%
0.19
Both
3
23%
0.09
Other
1
8%
0.03
Total
13
100%
0.41
*†per 100000 population, estimates per US Census

#
0
0
0
0
0

Deaths
%
Rate†
0%
0.00
0%
0.00
0%
0.00
0%
0.00
0%
0.00

CFR
0%
0%
0%
0%
0%

TABLE 1-Cases & Deaths of IMD in MC by Syndrome in 2002
Cases
%
Rate*
Syndrome
Meningitis
8
40%
0.24
Bacteremia
8
40%
0.24
Both
3
15%
0.09
Other
1
5%
0.03
Total
20
100%
0.61
*†per 100000 population, estimates per US Census
#

#
2
1
2
0
5

Deaths
%
Rate†
40%
0.06
20%
0.03
40%
0.06
0%
0.00
100%
0.15

CFR
10%
5%
10%
0%
25%

TABLE 1-Cases & Deaths of IMD in MC by Syndrome in 2003
Cases
#
%
Rate*
Syndrome
Meningitis
4
24%
0.12
Bacteremia
8
47%
0.24
Both
5
29%
0.15
Other
0
0%
0.00
Total
17
100%
0.50
*†per 100000 population, estimates per US Census

27

#

Deaths
Rate†
0%
0.00
100%
0.03
0%
0.00
0%
0.00
100%
0.03

%
0
1
0
0
1

CFR
0%
6%
0%
0%
6%

TABLE 1-Cases & Deaths of IMD in MC by Syndrome in 2004
Cases
#
%
Rate*
Syndrome
Meningitis
4
36%
0.11
Bacteremia
5
45%
0.14
Both
1
9%
0.03
Other
1
9%
0.03
Total
11
100%
0.31
*†per 100000 population, estimates per US Census

#
0
0
0
0
0

Deaths
%
Rate†
0%
0.00
0%
0.00
0%
0.00
0%
0.00
0%
0.00

CFR
0%
0%
0%
0%
0%

TABLE 1-Cases & Deaths of IMD in MC by Syndrome in 2005
Cases
#
%
Rate*
Syndrome
Meningitis
6
32%
0.17
Bacteremia
10
53%
0.28
Both
3
16%
0.08
Other
0
0%
0.00
Total
19
100%
0.52
*†per 100000 population, estimates per US Census

#
0
1
0
0
1

Deaths
%
Rate†
0%
0.00
100%
0.03
0%
0.00
0%
0.00
100%
0.03

CFR
0%
5%
0%
0%
5%

TABLE 1-Cases & Deaths of IMD in MC by Syndrome in 2006, 1/1-6/30
Syndrome
Meningitis
Bacteremia
Both
Other
Total

#
2
3
0
0
5

Cases
%
40%
60%
0%
0%
100%

Rate

#
1
1
0
0
2

Deaths
%
Rate
50%
50%
0%
0%
100%

CFR
20%
20%
0%
0%
40%

TABLE 1-Cases & Deaths of IMD in MC by Syndrome
1/1/2000-6/30/2006
Syndrome
Meningitis
Bacteremia
Both
Other
Total

#
34
57
19
3
113

Cases
%
30%
50%
17%
3%
100%

Deaths
Rate

28

#
3
7
2
0
12

%
25%
58%
17%
0%
100%

Rate

CFR
3%
6%
2%
0%
11%

B. Cases & Deaths of Invasive Meningococcal Disease(IMD) in
Maricopa County(MC) by Race/Ethnicity, 2000-2006, per year
TABLE 2-Cases & Deaths of IMD in MC by Race/Ethnicity in 2000
Cases
Deaths
#
%
Rate*
#
%
Rate†
Race/Ethnicity
White
12
43%
0.58
2
67%
0.10
Hispanic
10
36%
1.32
1
33%
0.13
Black
3
11%
2.71
0
0%
0.00
Am Indian/Alaskan Native
2
7%
4.04
0
0%
0.00
Asian/Pacific Islander
1
4%
1.41
0
0%
0.00
Other
0
0%
0.00
0
0%
0.00
Total
28
100%
0.90
3
100%
0.10
§Combo B, A/A, A/PI,
Other
6
21%
2.24
0
0%
0.00
*†per 100000 population, estimates per US Census
§ Total of Black, Am Indian/Alaskan Native, Asian/Pacific Islander, and Other

CFR
7%
4%
0%
0%
0%
0%
11%
0%

TABLE 2-Cases & Deaths of IMD in MC by Race/Ethnicity in 2001
Cases

Deaths

#
%
Rate*
#
%
Race/Ethnicity
White
6
46%
0.29
0
0%
Hispanic
7
54%
0.86
0
0%
Black
0
0%
0.00
0
0%
Am Indian/Alaskan Native
0
0%
0.00
0
0%
Asian/Pacific Islander
0
0%
0.00
0
0%
Other
0
0%
0.00
0
0%
Total
13
100%
0.41
0
0%
§Combo B, A/A, A/PI,
Other
0
0%
0.00
0
0%
*†per 100000 population, estimates per US Census
§ Total of Black, Am Indian/Alaskan Native, Asian/Pacific Islander, and Other

Rate†
0.00
0.00
0.00
0.00
0.00
0.00
0.00

CFR
0%
0%
0%
0%
0%
0%
0%

0.00

0%

TABLE 2-Cases & Deaths of IMD in MC by Race/Ethnicity in 2002
Cases
#
%
Race/Ethnicity
White
10
50%
Hispanic
10
50%
Black
0
0%
Am Indian/Alaskan Native
0
0%
Asian/Pacific Islander
0
0%
Other
0
0%
Total
20
100%
§Combo B, A/A, A/PI, Other
0
0%
*†per 100000 population, estimates per US Census

Deaths
Rate*
0.47
1.15
0.00
0.00
0.00
0.00
0.61
0.00

§ Total of Black, Am Indian/Alaskan Native, Asian/Pacific Islander,
and Other

29

#

%
2
3
0
0
0
0
5
0

40%
60%
0%
0%
0%
0%
100%
0%

Rate†
0.09
0.35
0.00
0.00
0.00
0.00
0.15
0.00

CFR
10%
15%
0%
0%
0%
0%
25%
0%

TABLE 2-Cases & Deaths of IMD in MC by Race/Ethnicity in 2003
Cases

Deaths

#
%
Rate*
#
%
Race/Ethnicity
White
8
47%
0.37
0
0%
Hispanic
7
41%
0.76
0
0%
Black
0
0%
0.00
0
0%
Am Indian/Alaskan Native
1
6%
1.81
1
100%
Asian/Pacific Islander
0
0%
0.00
0
0%
Other
1
6%
2.35
0
0%
Total
17
100%
0.50
1
100%
§Combo B, A/A, A/PI,
Other
2
12%
0.65
1
100%
*†per 100000 population, estimates per US Census
§ Total of Black, Am Indian/Alaskan Native, Asian/Pacific Islander, and Other

Rate†
0.00
0.00
0.00
1.81
0.00
0.00
0.03

CFR
0%
0%
0%
6%
0%
0%
6%

0.33

6%

0%
0%
0%
0%
0%
0%
0%

Rate†
0.00
0.00
0.00
0.00
0.00
0.00
0.00

CFR
0%
0%
0%
0%
0%
0%
0%

0%

0.00

0%

Rate†
0.00
0.00
0.72
0.00
0.00
0.00
0.03

CFR
0%
0%
5%
0%
0%
0%
5%

0.29

5%

TABLE 2-Cases & Deaths of IMD in MC by Race/Ethnicity in 2004
Cases

Deaths

#
%
Rate*
#
%
Race/Ethnicity
White
8
73%
0.37
0
Hispanic
2
18%
0.21
0
Black
1
9%
0.76
0
Am Indian/Alaskan Native
0
0%
0.00
0
Asian/Pacific Islander
0
0%
0.00
0
Other
0
0%
0.00
0
Total
11
100%
0.31
0
§Combo B, A/A, A/PI,
Other
1
9%
0.31
0
*†per 100000 population, estimates per US Census
§ Total of Black, Am Indian/Alaskan Native, Asian/Pacific Islander, and Other

TABLE 2-Cases & Deaths of IMD in MC by Race/Ethnicity in 2005
Cases

Deaths

#
%
Rate*
#
%
Race/Ethnicity
White
12
63%
0.54
0
0%
Hispanic
6
32%
0.58
0
0%
Black
1
5%
0.72
1
100%
Am Indian/Alaskan Native
0
0%
0.00
0
0%
Asian/Pacific Islander
0
0%
0.00
0
0%
Other
0
0%
0.00
0
0%
Total
19
100%
0.52
1
100%
§Combo B, A/A, A/PI,
Other
1
5%
0.29
1
100%
*†per 100000 population, estimates per US Census
§ Total of Black, Am Indian/Alaskan Native, Asian/Pacific Islander, and Other

30

TABLE 2-Cases & Deaths of IMD in MC by Race/Ethnicity in 2006, 1/1-6/30
Cases

Deaths

#
%
Rate
#
%
Race/Ethnicity
White
2
40%
1
50%
Hispanic
2
40%
0
0%
Black
1
20%
1
50%
Am Indian/Alaskan Native
0
0%
0
0%
Asian/Pacific Islander
0
0%
0
0%
Other
0
0%
0
0%
Total
5
100%
2
100%
§Combo B, A/A, A/PI,
Other
1
20%
1
50%
§ Total of Black, Am Indian/Alaskan Native, Asian/Pacific Islander, and Other

Rate

CFR
20%
0%
20%
0%
0%
0%
40%
20%

TABLE 2-Cases & Deaths of IMD in MC by Race/Ethnicity
1/1/2000-6/30/2006
Cases
#
%
Rate
#
%
Race/Ethnicity
White
58
51%
5
42%
Hispanic
44
39%
4
33%
Black
6
5%
2
17%
Am Indian/Alaskan Native
3
3%
1
8%
Asian/Pacific Islander
1
1%
0
0%
Other
1
1%
0
0%
Total
113
100%
12
100%
§Combo B, A/A, A/PI,
Other
11
10%
3
25%
§ Total of Black, Am Indian/Alaskan Native, Asian/Pacific Islander, and Other

31

Deaths
Rate

CFR
4%
4%
2%
1%
0%
0%
11%
3%

C. Cases & Deaths of Invasive Meningococcal Disease(IMD) in
Maricopa County(MC) by Gender, 2000-2006, per year
TABLE 3-Cases & Deaths of IMD in MC by Gender in 2000
Cases
#
%
Rate*
Sex
Male
14
50%
0.90
Female
14
50%
0.90
Total
28
100%
0.90
*†per 100000 population, estimates per US Census

Deaths
Rate†
0%
0.00
100%
0.19
100%
0.10

#

%
0
3
3

CFR
0%
11%
11%

TABLE 3-Cases & Deaths of IMD in MC by Gender in 2001
Cases
#
%
Rate*
Sex
Male
6
46%
0.37
Female
7
54%
0.44
Total
13
100%
0.41
*†per 100000 population, estimates per US Census

#
0
0
0

Deaths
%
Rate†
0%
0.00
0%
0.00
0%
0.00

CFR
0%
0%
0%

TABLE 3-Cases & Deaths of IMD in MC by Gender in 2002
Cases
#
%
Rate*
Sex
Male
11
55%
0.67
Female
9
45%
0.55
Total
20
100%
0.61
*†per 100000 population, estimates per US Census

Deaths
%
Rate†
40%
0.12
60%
0.18
100%
0.15

#
2
3
5

CFR
10%
15%
25%

TABLE 3-Cases & Deaths of IMD in MC by Gender in 2003
Cases
#
%
Rate*
Sex
Male
8
47%
0.47
Female
9
53%
0.53
Total
17
100%
0.50
*†per 100000 population, estimates per US Census

Deaths
Rate†
0%
0.00
33%
0.06
100%
0.03

#

%
0
1
1

CFR
0%
6%
6%

TABLE 3-Cases & Deaths of IMD in MC by Gender in 2004
Cases
#
%
Rate*
Sex
Male
6
55%
0.34
Female
5
45%
0.29
Total
11
100%
0.31
*†per 100000 population, estimates per US Census

32

#
0
0
0

Deaths
%
Rate†
0%
0.00
0%
0.00
0%
0.00

CFR
0%
0%
0%

TABLE 3-Cases & Deaths of IMD in MC by Gender in 2005
Cases
#
%
Rate*
Sex
Male
10
53%
0.55
Female
9
47%
0.50
Total
19
100%
0.52
*†per 100000 population, estimates per US Census

#
1
0
1

Deaths
%
Rate†
100%
0.05
0%
0.00
100%
0.03

CFR
5%
0%
5%

TABLE 3-Cases & Deaths of IMD in MC by Gender in 2006, 1/1-6/30
Sex
Male
Female
Total

#
2
3
5

Cases
%
40%
60%
100%

Rate

#
1
1
2

Deaths
%
Rate
50%
50%
100%

CFR
20%
20%
40%

TABLE 3-Cases & Deaths of IMD in MC by Gender
1/1/2000-6/30/2006
Sex
Male
Female
Total

#
57
56
113

Cases
%
50%
50%
100%

Rate

#
4
8
12

33

Deaths
%
Rate
33%
67%
100%

CFR
4%
7%
11%

D. Cases & Deaths of Invasive Meningococcal Disease(IMD) in
Maricopa County(MC) by Age, 2000-2006, per year
TABLE 4-Cases & Deaths of IMD in MC by Age in 2000
Cases
#
%
Rate*
#
Age
<1 year
6
21%
1 year
3
11%
2-4 years
1
4%
§0-4 years
10
36%
4.10
5-9 years
1
4%
0.42
10-13 years
3
11%
14-17 years
2
7%
18-24 years
2
7%
§10-24years
7
25%
1.05
25-64 years
5
18%
0.32
65+ years
5
18%
1.38
Total
28
100%
0.90
*†per 100000 population, estimates per US Census
§Combined age groups for rate calculation purposes

Deaths
Rate†
0%
0%
33%
33%
0.41
0%
0.00
0%
0%
0%
0%
0.00
0%
0.00
67%
0.55
100%
0.10
%

0
0
1
1
0
0
0
0
0
0
2
3

CFR
0%
0%
4%
4%
0%
0%
0%
0%
0%
0%
7%
11%

TABLE 4-Cases & Deaths of IMD in MC by Age in 2001
Cases
#
%
Rate*
#
Age
<1 year
2
15%
1 year
1
8%
2-4 years
2
15%
§0-4 years
5
38%
1.92
5-9 years
1
8%
0.40
10-13 years
0
0%
14-17 years
1
8%
18-24 years
0
0%
§10-24years
1
8%
0.14
25-64 years
4
31%
0.24
65+ years
2
15%
0.54
Total
13
100%
0.41
*†per 100000 population, estimates per US Census
§Combined age groups for rate calculation purposes

34

%
0
0
0
0
0
0
0
0
0
0
0
0

Deaths
Rate†
0%
0%
0%
0%
0.00
0%
0.00
0%
0%
0%
0%
0.00
0%
0.00
0%
0.00
0%
0.00

CFR
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%

TABLE 4-Cases & Deaths of IMD in MC by Age in 2002
Cases
#
%
Rate*
#
Age
<1 year
5
25%
1 year
0
0%
2-4 years
2
10%
§0-4 years
7
35%
2.59
5-9 years
1
5%
0.39
10-13 years
0
0%
14-17 years
2
10%
18-24 years
7
35%
§10-24years
9
45%
1.27
25-64 years
3
15%
0.18
65+ years
0
0%
0.00
Total
20
100%
0.61
*†per 100000 population, estimates per US Census
§Combined age groups for rate calculation purposes

2
0
0
2
0
0
1
2
3
0
0
5

Deaths
%
Rate†
40%
0%
0%
40%
0.74
0%
0.00
0%
20%
40%
60%
0.42
0%
0.00
0%
0.00
100%
0.15

CFR
10%
0%
0%
10%
0%
0%
5%
10%
15%
0%
0%
25%

TABLE 4-Cases & Deaths of IMD in MC by Age in 2003
Cases
#
%
Rate*
#
Age
<1 year
5
29%
1 year
0
0%
2-4 years
3
18%
§0-4 years
8
47%
2.85
5-9 years
2
12%
0.76
10-13 years
0
0%
14-17 years
1
6%
18-24 years
3
18%
§10-24years
4
24%
0.55
25-64 years
3
18%
0.17
65+ years
0
0%
0.00
Total
17
100%
0.50
*†per 100000 population, estimates per US Census
§Combined age groups for rate calculation purposes

35

1
0
0
1
0
0
0
0
0
0
0
1

Deaths
%
Rate†
100%
0%
0%
100%
0.36
0%
0.00
0%
0%
0%
0%
0.00
0%
0%
0.00
100%
0.03

CFR
6%
0%
0%
6%
0%
0%
0%
0%
0%
0%
0%
6%

TABLE 4-Cases & Deaths of IMD in MC by Age in 2004
Cases
#
%
Rate*
#
Age
<1 year
1
9%
1 year
0
0%
2-4 years
1
9%
§0-4 years
2
18%
0.69
5-9 years
1
9%
0.37
10-13 years
2
18%
14-17 years
1
9%
18-24 years
0
0%
§10-24years
3
27%
0.40
25-64 years
3
27%
0.17
65+ years
2
18%
0.51
Total
11
100%
0.31
*†per 100000 population, estimates per US Census
§Combined age groups for rate calculation purposes

%
0
0
0
0
0
0
0
0
0
0
0
0

Deaths
Rate†
0%
0%
0%
0%
0.00
0%
0.00
0%
0%
0%
0%
0.00
0%
0.00
0%
0.00
0%
0.00

CFR
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%

TABLE 4-Cases & Deaths of IMD in MC by Age in 2005
Cases
#
%
Rate*
#
Age
<1 year
0
0%
1 year
1
5%
2-4 years
1
5%
§0-4 years
2
11%
0.67
5-9 years
1
5%
0.36
10-13 years
0
0%
14-17 years
3
16%
18-24 years
3
16%
§10-24years
6
32%
0.78
25-64 years
8
42%
0.42
65+ years
2
11%
0.50
Total
19
100%
0.52
*†per 100000 population, estimates per US Census
§Combined age groups for rate calculation purposes

36

Deaths
Rate†
0%
0%
100%
100%
0.33
0%
0.00
0%
0%
0%
0%
0.00
0%
0.00
0%
0.00
100%
0.03
%

0
0
1
1
0
0
0
0
0
0
0
1

CFR
0%
0%
5%
5%
0%
0%
0%
0%
0%
0%
0%
5%

TABLE 4-Cases & Deaths of IMD in MC by Age in 2006, 1/1-6/30
Age
<1 year
1 year
2-4 years
§0-4 years
5-9 years
10-13 years
14-17 years
18-24 years
§10-24 years
25-64 years
65+ years
Total
§Combined age groups

#
0
0
2
2
0
0
0
2
2
1
0
5

Cases
%
0%
0%
40%
40%
0%
0%
0%
40%
40%
20%
0%
100%

Rate

#
0
0
0
0
0
0
0
1
1
1
0
2

Deaths
%
Rate
0%
0%
0%
0%
0%
0%
0%
50%
50%
50%
0%
100%

CFR
0%
0%
0%
0%
0%
0%
0%
20%
20%
20%
0%
40%

TABLE 4-Cases & Deaths of IMD in MC by Age
1/1/2000-6/30/2006
Age
<1 year
1 year
2-4 years
§0-4 years
5-9 years
10-13 years
14-17 years
18-24 years
§10-24years
25-64 years
65+ years
Total
§Combined age groups

Cases
#
19
5
12
36
7
5
10
17
32
27
11
113

%
17%
4%
11%
32%
6%
4%
9%
15%
28%
24%
10%
100%

Rate

#
3
0
2
5
0
0
1
3
4
1
2
12

37

Deaths
%
25%
0%
17%
42%
0%
0%
8%
25%
33%
8%
17%
100%

Rate

CFR
3%
0%
2%
4%
0%
0%
1%
3%
4%
1%
2%
11%

E. Cases & Deaths of Invasive Meningococcal Disease(IMD) in
Maricopa County(MC) by Serogroup, 2000-2006, per year
TABLE 5-Cases & Deaths of IMD in MC by Serogroup in 2000
Cases
#
%
Rate*
Serogroup
Group B
5
18%
0.16
Group C
1
4%
0.03
Group Y
10
36%
0.32
§Others
2
7%
0.06
Not Groupable
7
25%
0.23
Unknown
3
11%
0.10
Total
28
100%
0.90
*†per 100000 population, estimates per US Census
§Others=A & W-135

Deaths
%
0%
0%
67%
33%
0%
0%
100%

#
0
0
2
1
0
0
3

Rate†
0.00
0.00
0.06
0.03
0.00
0.00
0.10

CFR
0%
0%
7%
4%
0%
0%
11%

TABLE 5-Cases & Deaths of IMD in MC by Serogroup in 2001
Cases
#
%
Rate*
Serogroup
Group B
8
62%
0.25
Group C
0
0%
0.00
Group Y
3
23%
0.09
§Others
0
0%
0.00
Not Groupable
2
15%
0.06
Unknown
0
0%
0.00
Total
13
100%
0.41
*†per 100000 population, estimates per US Census
§Others=A & W-135

#
0
0
0
0
0
0
0

Deaths
%
Rate†
0%
0.00
0%
0.00
0%
0.00
0%
0.00
0%
0.00
0%
0.00
0%
0.00

CFR
0%
0%
0%
0%
0%
0%
0%

TABLE 5-Cases & Deaths of IMD in MC by Serogroup in 2002
Cases
%
Rate*
Serogroup
Group B
10
50%
0.30
Group C
6
30%
0.18
Group Y
2
10%
0.06
§Others
1
5%
0.03
Not Groupable
0
0%
0.00
Unknown
1
5%
0.03
Total
20
100%
0.61
*†per 100000 population, estimates per US Census
§Others=A & W-135
#

38

#
4
0
0
0
0
1
5

Deaths
%
Rate†
80%
0.12
0%
0.00
0%
0.00
0%
0.00
0%
0.00
20%
0.03
100%
0.15

CFR
20%
0%
0%
0%
0%
5%
25%

TABLE 5-Cases & Deaths of IMD in MC by Serogroup in 2003
Cases
#
%
Rate*
Serogroup
Group B
2
12%
0.06
Group C
5
29%
0.15
Group Y
2
12%
0.06
§Others
0
0%
0.00
Not Groupable
6
35%
0.18
Unknown
2
12%
0.06
Total
17
100%
0.50
*†per 100000 population, estimates per US Census
§Others=A & W-135

Deaths
Rate†
0%
0.00
0%
0.00
0%
0.00
0%
0.00
0%
0.00
100%
0.03
100%
0.03

#

%
0
0
0
0
0
1
1

CFR
0%
0%
0%
0%
0%
6%
6%

TABLE 5-Cases & Deaths of IMD in MC by Serogroup in 2004
Cases
#
%
Rate*
Serogroup
Group B
0
0%
0.00
Group C
2
18%
0.06
Group Y
3
27%
0.09
§Others
0
0%
0.00
Not Groupable
1
9%
0.03
Unknown
5
45%
0.14
Total
11
100%
0.31
*†per 100000 population, estimates per US Census
§Others=A & W-135

Deaths
%
Rate†
0%
0.00
0%
0.00
0%
0.00
0%
0.00
0%
0.00
0%
0.00
0%
0.00

#
0
0
0
0
0
0
0

CFR
0%
0%
0%
0%
0%
0%
0%

TABLE 5-Cases & Deaths of IMD in MC by Serogroup in 2005
Cases
#
%
Rate*
Serogroup
Group B
4
21%
0.11
Group C
5
26%
0.14
Group Y
2
11%
0.06
§Others
1
5%
0.03
Not Groupable
2
11%
0.06
Unknown
5
26%
0.14
Total
19
100%
0.52
*†per 100000 population, estimates per US Census
§Others=A & W-135

Deaths
%
100%
0%
0%
0%
0%
0%
100%

#
1
0
0
0
0
0
1

Rate†
0.03
0.00
0.00
0.00
0.00
0.00
0.03

CFR
5%
0%
0%
0%
0%
0%
5%

TABLE 5-Cases & Deaths of IMD in MC by Serogroup in 2006,1/1-6/30
Serogroup
Group B
Group C
Group Y
§Others
Not Groupable
Unknown
Total
§Others=A & W-135

#
0
0
2
0
0
3
5

Cases
%
0%
0%
40%
0%
0%
60%
100%

39

Rate

#
0
0
1
0
0
1
2

Deaths
%
Rate
0%
0%
33%
0%
0%
33%
100%

CFR
0%
0%
20%
0%
0%
20%
40%

TABLE 5-Cases & Deaths of IMD in MC by Serogroup
2000-2005
Cases
#
%
Serogroup
Group B
29
27%
Group C
19
18%
Group Y
22
20%
§Others
4
4%
Not Groupable
18
17%
Unknown
16
15%
Total
108
100%
*†per 100000 population, estimates per US Census
§Others=A & W-135

Rate
0.14
0.09
0.11
0.02
0.09
0.08
0.54

#
5
0
2
1
0
2
10

Deaths
%
Rate
42%
0%
17%
8%
0%
17%
83%

CFR
5%
0%
2%
1%
0%
2%
9%

TABLE 5-Cases & Death of IMD in MC by Serogroup
1/1/2000-6/302006
Serogroup
Group B
Group C
Group Y
§Others
Not Groupable
Unknown
Total
§Others=A & W-135

#
29
19
24
4
18
19
113

Cases
%
26%
17%
21%
4%
16%
17%
100%

Rate

#
5
0
3
1
0
3
12

40

Deaths
%
42%
0%
25%
8%
0%
25%
100%

Rate

CFR
4%
0%
3%
1%
0%
3%
11%

F. Invasive Meningococcal Disease(IMD) in Maricopa County(MC) by
Serogroup and Age, 2000-2006, per year
TABLE 9- IMD in MC by Serogroup and Age-2000
Serogroup
Not
Age
<1 year
Serogroup by age
Age by serogroup
1 year
Serogroup by age
Age by serogroup
2-4 years
Serogroup by age
Age by serogroup
5-9 years
Serogroup by age
Age by serogroup
10-13 years
Serogroup by age
Age by serogroup
14-17 years
Serogroup by age
Age by serogroup
18-24 years
Serogroup by age
Age by serogroup
25-64 years
Serogroup by age
Age by serogroup
65+ years
Serogroup by age
Age by serogroup
Total

Group
B
#
%
%

#
%
%
#
%
%
#
%
%
#
%
%
#
%
%
#
%
%
#
%
%
#
%
%
#
%
Age by serogroup %
§Others=A & W-135

1
17%
20%
0
0%
0%
0
0%
0%
0
0%
0%
1
33%
20%
1
50%
20%
1
50%
20%
1
20%
20%
0
0%
0%
5
18%
100%

Group
C
0
0%
0%
0
0%
0%
0
0%
0%
1
100%
100%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
1
4%
100%

41

Group
Y
0
0%
0%
2
67%
20%
0
0%
0%
0
0%
0%
1
33%
10%
1
50%
10%
0
0%
0%
2
40%
20%
4
80%
40%
10
36%
100%

§Others
0
0%
0%
1
33%
50%
1
100%
50%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
2
7%
100%

Groupable
3
50%
43%
0
0%
0%
0
0%
0%
0
0%
0%
1
33%
14%
0
0%
0%
1
50%
14%
1
20%
14%
1
20%
14%
7
25%
100%

Unknown
2
33%
67%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
1
20%
33%
0
0%
0%
3
11%
100%

Total
6
100%
21%
3
100%
11%
1
100%
4%
1
100%
4%
3
100%
11%
2
100%
7%
2
100%
7%
5
100%
18%
5
100%
18%
28
100%

TABLE 9- IMD in MC by Serogroup and Age-2001
Serogroup
Not
Age
<1 year
#
Serogroup by age %
Age by serogroup %
1 year
#
Serogroup by age %
Age by serogroup %
2-4 years
#
Serogroup by age %
Age by serogroup %
5-9 years
#
Serogroup by age %
Age by serogroup %
10-13 years
#
Serogroup by age %
Age by serogroup %
14-17 years
#
Serogroup by age %
Age by serogroup %
18-24 years
#
Serogroup by age %
Age by serogroup %
25-64 years
#
Serogroup by age %
Age by serogroup %
65+ years
#
Serogroup by age %
Age by serogroup %
Total
#
Serogroup by age %
Age by serogroup %
§Others=A & W-135

Group
B
1
50%
13%
0
0%
0%
2
100%
25%
1
100%
13%
0
0%
0%
0
0%
0%
0
0%
0%
3
75%
38%
1
50%
13%
8
62%
100%

Group
C
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%

42

Group
Y
1
50%
33%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
1
100%
33%
0
0%
0%
0
0%
0%
1
50%
33%
3
23%
100%

§Others
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%

Groupable
0
0%
0%
1
100%
50%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
1
25%
50%
0
0%
0%
2
15%
100%

Unknown
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%

Total
2
100%
15%
1
100%
8%
2
100%
15%
1
100%
8%
0
0%
0%
1
100%
8%
0
0%
0%
4
100%
31%
2
100%
15%
13
100%

TABLE 9- IMD in MC by Serogroup and Age-2002
Serogroup
Not
Age
<1 year
#
Serogroup by age %
Age by serogroup %
1 year
#
Serogroup by age %
Age by serogroup %
2-4 years
#
Serogroup by age %
Age by serogroup %
5-9 years
#
Serogroup by age %
Age by serogroup %
10-13 years
#
Serogroup by age %
Age by serogroup %
14-17 years
#
Serogroup by age %
Age by serogroup %
18-24 years
#
Serogroup by age %
Age by serogroup %
25-64 years
#
Serogroup by age %
Age by serogroup %
65+ years
#
Serogroup by age %
Age by serogroup %
Total
#
Serogroup by age %
Age by serogroup %
§Others=A & W-135

Group
B
4
80%
40%
0
0%
0%
1
50%
10%
0
0%
0%
0
0%
0%
0
0%
0%
5
71%
50%
0
0%
0%
0
0%
0%
10
50%
100%

Group
C
0
0%
0%
0
0%
0%
0
0%
0%
1
100%
14%
0
0%
0%
0
0%
0%
2
29%
29%
3
100%
43%
0
0%
0%
6
30%
86%

43

Group
Y
1
20%
50%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
1
50%
50%
0
0%
0%
0
0%
0%
0
0%
0%
2
10%
100%

§Others
0
0%
0%
0
0%
0%
1
50%
100%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
1
5%
100%

Groupable
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%

Unknown
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
1
50%
100%
0
0%
0%
0
0%
0%
0
0%
0%
1
5%
100%

Total
5
100%
25%
0
0%
0%
2
100%
10%
1
0%
5%
0
0%
0%
2
100%
10%
7
100%
35%
3
100%
15%
0
0%
0%
20
100%

TABLE 9- IMD in MC by Serogroup and Age-2003
Serogroup
Not
Age
<1 year
#
Serogroup by age %
Age by serogroup %
1 year
#
Serogroup by age %
Age by serogroup %
2-4 years
#
Serogroup by age %
Age by serogroup %
5-9 years
#
Serogroup by age %
Age by serogroup %
10-13 years
#
Serogroup by age %
Age by serogroup %
14-17 years
#
Serogroup by age %
Age by serogroup %
18-24 years
#
Serogroup by age %
Age by serogroup %
25-64 years
#
Serogroup by age %
Age by serogroup %
65+ years
#
Serogroup by age %
Age by serogroup %
Total
#
Serogroup by age %
Age by serogroup %
§Others=A & W-135

Group
B
0
0%
0%
0
0%
0%
1
33%
50%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
1
33%
50%
0
0%
0%
2
0%
100%

Group
C
0
0%
0%
0
0%
0%
0
0%
0%
1
50%
20%
0
0%
0%
1
100%
20%
2
67%
40%
1
33%
20%
0
0%
0%
5
0%
100%

44

Group
Y
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
1
33%
50%
1
33%
50%
0
0%
0%
2
12%
100%

§Others
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%

Groupable
4
80%
67%
0
0%
0%
1
33%
17%
1
50%
17%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
6
35%
100%

Unknown
1
20%
50%
0
0%
0%
1
33%
50%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
2
12%
100%

Total
5
100%
29%
0
0%
0%
3
100%
18%
2
100%
12%
0
1%
0%
1
100%
6%
3
100%
18%
3
100%
18%
0
0%
0%
17
100%

TABLE 9- IMD in MC by Serogroup and Age-2004
Serogroup
Not
Age
<1 year
#
Serogroup by age %
Age by serogroup %
1 year
#
Serogroup by age %
Age by serogroup %
2-4 years
#
Serogroup by age %
Age by serogroup %
5-9 years
#
Serogroup by age %
Age by serogroup %
10-13 years
#
Serogroup by age %
Age by serogroup %
14-17 years
#
Serogroup by age %
Age by serogroup %
18-24 years
#
Serogroup by age %
Age by serogroup %
25-64 years
#
Serogroup by age %
Age by serogroup %
65+ years
#
Serogroup by age %
Age by serogroup %
Total
#
Serogroup by age %
Age by serogroup %
§Others=A & W-135

Group
B
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%

Group
C
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
1
50%
50%
0
0%
0%
0
0%
0%
1
33%
50%
0
0%
0%
2
18%
100%

45

Group
Y
1
100%
33%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
1
33%
33%
1
50%
33%
3
27%
100%

§Others
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%

Groupable
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
1
50%
100%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
1
9%
100%

Unknown
0
0%
0%
0
0%
0%
1
100%
20%
1
100%
20%
0
0%
0%
1
100%
20%
0
0%
0%
1
33%
20%
1
50%
20%
5
45%
100%

Total
1
100%
9%
0
0%
0%
1
100%
9%
1
100%
9%
2
100%
18%
1
100%
9%
0
0%
0%
3
100%
27%
2
100%
18%
11
100%

TABLE 9- IMD in MC by Serogroup and Age-2005
Serogroup
Not
Age
<1 year
#
Serogroup by age %
Age by serogroup %
1 year
#
Serogroup by age %
Age by serogroup %
2-4 years
#
Serogroup by age %
Age by serogroup %
5-9 years
#
Serogroup by age %
Age by serogroup %
10-13 years
#
Serogroup by age %
Age by serogroup %
14-17 years
#
Serogroup by age %
Age by serogroup %
18-24 years
#
Serogroup by age %
Age by serogroup %
25-64 years
#
Serogroup by age %
Age by serogroup %
65+ years
#
Serogroup by age %
Age by serogroup %
Total
#
Serogroup by age %
Age by serogroup %
§Others=A & W-135

Group
B
0
0%
0%
0
0%
0%
1
100%
25%
0
0%
0%
0
0%
0%
1
33%
25%
1
33%
25%
1
13%
25%
0
0%
0%
4
21%
100%

Group
C
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
1
33%
20%
1
33%
20%
3
38%
60%
0
0%
0%
5
26%
100%

46

Group
Y
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
2
25%
100%
0
0%
0%
2
11%
100%

§Others
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
1
50%
100%
1
5%
100%

Groupable
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
1
13%
50%
1
50%
50%
2
11%
100%

Unknown
0
0%
0%
1
100%
50%
0
0%
0%
1
100%
20%
0
0%
0%
1
33%
20%
1
33%
20%
1
13%
20%
0%
0%
5
26%
100%

Total
0
0%
0%
1
100%
5%
1
100%
5%
1
100%
5%
0
0%
0%
3
0%
16%
3
100%
16%
8
100%
42%
2
100%
11%
19
100%

TABLE 9- IMD in MC by Serogroup and Age-2006, 1/1-6/30
Serogroup
Not
Age
<1 year
#
Serogroup by age %
Age by serogroup %
1 year
#
Serogroup by age %
Age by serogroup %
2-4 years
#
Serogroup by age %
Age by serogroup %
5-9 years
#
Serogroup by age %
Age by serogroup %
10-13 years
#
Serogroup by age %
Age by serogroup %
14-17 years
#
Serogroup by age %
Age by serogroup %
18-24 years
#
Serogroup by age %
Age by serogroup %
25-64 years
#
Serogroup by age %
Age by serogroup %
65+ years
#
Serogroup by age %
Age by serogroup %
Total
#
%
Age by serogroup %
§Others=A & W-135

Group
B
0
0%
0%
0
0%
0%
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%

Group
C
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%

47

Group
Y
0
0%
0%
0
0%
0%
1
50%
50%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
1
100%
50%
0
0%
0%
2
40%
100%

§Others
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%

Groupable
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%

Unknown
0
0%
0%
0
0%
0%
1
50%
33%
0
0%
0%
0
0%
0%
0
0%
0%
2
100%
67%
0
0%
0%
0
0%
0%
3
60%
100%

Total
0
0%
0%
0
0%
0%
2
100%
40%
0
0%
0%
0
0%
0%
0
0%
0%
2
100%
40%
1
100%
20%
0
0%
0%
5
100%

TABLE 9-IMD in MC by Serogroup and Age 2000-2005
Serogroup
Not
Age
<1 year
Serogroup by age
Age by serogroup
1 year
Serogroup by age
Age by serogroup
2-4 years
Serogroup by age
Age by serogroup
5-9 years
Serogroup by age
Age by serogroup
10-13 years
Serogroup by age
Age by serogroup
14-17 years
Serogroup by age
Age by serogroup
18-24 years
Serogroup by age
Age by serogroup
25-64 years
Serogroup by age
Age by serogroup
65+ years
Serogroup by age
Age by serogroup
Total

Group
B
#
%
%

#
%
%
#
%
%
#
%
%
#
%
%
#
%
%
#
%
%
#
%
%
#
%
%
#
%
Age by serogroup %
§Others=A & W-135

6
32%
21%
0
0%
0%
5
50%
17%
1
14%
3%
1
20%
3%
2
20%
7%
7
47%
24%
6
23%
21%
1
8%
3%
29
27%
100%

Group
C
0
0%
0%
0
0%
0%
0
0%
0%
3
43%
16%
1
20%
5%
2
20%
11%
5
33%
26%
8
31%
42%
0
0%
0%
19
18%
100%

48

Group
Y
3
16%
14%
2
40%
9%
0
0%
0%
0
0%
0%
1
20%
5%
3
30%
14%
1
7%
5%
6
23%
27%
6
50%
27%
22
20%
100%

§Others
0
0%
0%
1
20%
25%
2
20%
50%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
1
8%
25%
4
4%
100%

Groupable
7
37%
39%
1
20%
6%
1
10%
6%
1
14%
6%
2
40%
11%
0
0%
0%
1
7%
6%
3
12%
17%
2
17%
11%
18
17%
100%

Unknown
3
16%
19%
1
20%
6%
2
20%
13%
2
29%
13%
0
0%
0%
3
30%
19%
1
7%
6%
3
12%
19%
1
8%
6%
16
15%
100%

Total
19
100%
18%
5
100%
5%
10
100%
9%
7
100%
6%
5
100%
5%
10
100%
9%
15
100%
14%
26
100%
24%
11
92%
10%
108
100%

TABLE 9- IMD in MC by Serogroup and Age
1/1/2000-6/30/2006
Serogroup
Not
Age
<1 year
Serogroup by age
Age by serogroup
1 year
Serogroup by age
Age by serogroup
2-4 years
Serogroup by age
Age by serogroup
5-9 years
Serogroup by age
Age by serogroup
10-13 years
Serogroup by age
Age by serogroup
14-17 years
Serogroup by age
Age by serogroup
18-24 years
Serogroup by age
Age by serogroup
25-64 years
Serogroup by age
Age by serogroup
65+ years
Serogroup by age
Age by serogroup
Total

Group
B
#
%
%

#
%
%
#
%
%
#
%
%
#
%
%
#
%
%
#
%
%
#
%
%
#
%
%
#
%
Age by serogroup %
§Others=A & W-135

6
32%
21%
0
0%
0%
5
42%
17%
1
14%
3%
1
20%
3%
2
20%
7%
7
41%
24%
6
22%
21%
1
8%
3%
29
26%
100%

Group
C
0
0%
0%
0
0%
0%
0
0%
0%
3
43%
16%
1
20%
5%
2
20%
11%
5
29%
26%
8
30%
42%
0
0%
0%
19
17%
100%

49

Group
Y
3
16%
13%
2
40%
8%
1
8%
4%
0
0%
0%
1
20%
4%
3
30%
13%
1
6%
4%
7
26%
29%
6
50%
25%
24
21%
100%

§Others
0
0%
0%
1
20%
25%
2
17%
50%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
1
8%
25%
4
4%
100%

Groupable
7
37%
39%
1
20%
6%
1
8%
6%
1
14%
6%
2
40%
11%
0
0%
0%
1
6%
6%
3
11%
17%
2
17%
11%
18
16%
100%

Unknown
3
16%
16%
1
20%
5%
3
25%
16%
2
29%
11%
0
0%
0%
3
30%
16%
3
18%
16%
3
11%
16%
1
8%
5%
19
17%
100%

Total
19
100%
17%
5
100%
4%
12
100%
11%
7
100%
6%
5
100%
4%
10
100%
9%
17
100%
15%
27
100%
24%
11
92%
10%
113
100%

G. Invasive Meningococcal Disease(IMD) in Maricopa County(MC) by
Serogroup and Race/Ethnicity, 2000-2006, per year
TABLE 7- IMD in MC by Serogroup and Race/Ethnicity-2000
Serogroup
Not
Race/Ethnicity
White
#
Serogroup by race %
Race by serogroup %
Hispanic
#
Serogroup by race %
Race by serogroup %
Black
#
Serogroup by race %
Race by serogroup %
Am Indian/Al Native #
Serogroup by race %
Race by serogroup %
Asian/Pacific Islander#
Serogroup by race %
Race by serogroup %
Unknown
#
Serogroup by race %
Race by serogroup %
Total
#
%
Race by serogroup %
§Others=A & W-135

Group
B
2
17%
40%
1
10%
20%
0
0%
0%
2
100%
40%
0
0%
0%
0
0%
0%
5
18%
100%

Group
C
1
8%
100%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
1
4%
100%

50

Group Y
5
42%
50%
3
30%
30%
2
67%
20%
0
0%
0%
0
0%
0%
0
0%
0%
10
36%
100%

§Others
0
0%
0%
2
20%
100%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
2
7%
100%

Groupable
4
33%
57%
3
30%
43%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
7
25%
100%

Unknown
0
0%
0%
1
10%
33%
1
33%
33%
0
11%
0%
1
100%
33%
0
0%
0%
3
11%
100%

Total
12
100%
43%
10
100%
36%
3
100%
11%
2
100%
7%
1
100%
4%
0
100%
0%
28
100%

TABLE 7- IMD in MC by Serogroup and Race/Ethnicity-2001
Serogroup
Not
Race/Ethnicity
White
#
Serogroup by race %
Race by serogroup %
Hispanic
#
Serogroup by race %
Race by serogroup %
Black
#
Serogroup by race %
Race by serogroup %
Am Indian/Al Native #
Serogroup by race %
Race by serogroup %
Asian/Pacific Islander#
Serogroup by race %
Race by serogroup %
Unknown
#
Serogroup by race %
Race by serogroup %
Total
#
%
Race by serogroup %
§Others=A & W-135

Group
B
3
50%
38%
5
71%
63%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
8
62%
100%

Group
C
2
33%
67%
1
14%
33%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
3
23%
100%

51

Group Y
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%

§Others
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%

Groupable
1
17%
50%
1
14%
50%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
2
15%
100%

Unknown
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%

Total
6
100%
46%
7
100%
54%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
13
100%

TABLE 7- IMD in MC by Serogroup and Race/Ethnicity-2002
Serogroup
Not
Race/Ethnicity
White
#
Serogroup by race %
Race by serogroup %
Hispanic
#
Serogroup by race %
Race by serogroup %
Black
#
Serogroup by race %
Race by serogroup %
Am Indian/Al Native #
Serogroup by race %
Race by serogroup %
Asian/Pacific Islander#
Serogroup by race %
Race by serogroup %
Unknown
#
Serogroup by race %
Race by serogroup %
Total
#
%
Race by serogroup %
§Others=A & W-135

Group
B
5
50%
50%
5
50%
50%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
10
36%
100%

Group
C
4
40%
67%
2
20%
33%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
6
21%
100%

52

Group Y
0
0%
0%
2
20%
100%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
2
7%
100%

§Others
0
0%
0%
1
10%
100%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
1
4%
100%

Groupable
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%

Unknown
1
10%
100%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
1
4%
100%

Total
10
100%
50%
10
100%
50%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
20
100%

TABLE 7- IMD in MC by Serogroup and Race/Ethnicity-2003
Serogroup
Not
Race/Ethnicity
White
#
Serogroup by race %
Race by serogroup %
Hispanic
#
Serogroup by race %
Race by serogroup %
Black
#
Serogroup by race %
Race by serogroup %
Am Indian/Al Native #
Serogroup by race %
Race by serogroup %
Asian/Pacific Islander#
Serogroup by race %
Race by serogroup %
Unknown
#
Serogroup by race %
Race by serogroup %
Total
#
%
Race by serogroup %
§Others=A & W-135

Group
B
0
0%
0%
1
14%
50%
0
0%
0%
0
0%
0%
0
0%
0%
1
0%
50%
2
12%
40%

Group
C
4
50%
80%
1
14%
20%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
5
29%
100%

53

Group Y
1
13%
50%
1
14%
50%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
2
12%
100%

§Others
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%

Groupable
3
38%
50%
3
43%
50%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
6
35%
100%

Unknown
0
0%
0%
1
14%
50%
0
0%
0%
1
100%
50%
0
0%
0%
0%
0%
0%
2
12%
100%

Total
8
100%
47%
7
100%
41%
0
0%
0%
1
100%
6%
0
0%
0%
1
0%
6%
17
100%

TABLE 7- IMD in MC by Serogroup and Race/Ethnicity-2004
Serogroup
Not
Race/Ethnicity
White
#
Serogroup by race %
Race by serogroup %
Hispanic
#
Serogroup by race %
Race by serogroup %
Black
#
Serogroup by race %
Race by serogroup %
Am Indian/Al Native #
Serogroup by race %
Race by serogroup %
Asian/Pacific Islander#
Serogroup by race %
Race by serogroup %
Unknown
#
Serogroup by race %
Race by serogroup %
Total
#
%
Race by serogroup %
§Others=A & W-135

Group
B
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%

Group
C
1
13%
50%
0
0%
0%
1
100%
50%
0
25%
0%
0
0%
0%
0
0%
0%
2
7%
100%

54

Group Y
3
38%
100%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
3
11%
100%

§Others
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%

Groupable
0
0%
0%
1
50%
100%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
1
4%
100%

Unknown
4
50%
80%
1
50%
20%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
5
18%
100%

Total
8
100%
73%
2
100%
18%
1
100%
9%
0
0%
0%
0
0%
0%
0
0%
0%
11
100%

TABLE 7- IMD in MC by Serogroup and Race/Ethnicity-2005
Serogroup
Not
Race/Ethnicity
White
#
Serogroup by race %
Race by serogroup %
Hispanic
#
Serogroup by race %
Race by serogroup %
Black
#
Serogroup by race %
Race by serogroup %
Am Indian/Al Native #
Serogroup by race %
Race by serogroup %
Asian/Pacific Islander#
Serogroup by race %
Race by serogroup %
Unknown
#
Serogroup by race %
Race by serogroup %
Total
#
%
Race by serogroup %
§Others=A & W-135

Group
B
1
8%
25%
2
33%
50%
1
100%
25%
0
0%
0%
0
0%
0%
0
0%
0%
4
14%
100%

Group
C
2
17%
40%
3
50%
60%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
5
18%
100%

55

Group Y
1
8%
50%
1
17%
50%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
2
7%
100%

§Others
1
8%
100%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
1
4%
100%

Groupable
2
17%
100%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
2
7%
100%

Unknown
5
42%
100%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
5
18%
100%

Total
12
100%
63%
6
100%
32%
1
100%
5%
0
0%
0%
0
0%
0%
0
0%
0%
19
100%

TABLE 7- IMD in MC by Serogroup and Race/Ethnicity-2006, 1/1-6/30
Serogroup
Not
Race/Ethnicity
White
#
Serogroup by race %
Race by serogroup %
Hispanic
#
Serogroup by race %
Race by serogroup %
Black
#
Serogroup by race %
Race by serogroup %
Am Indian/Al Native #
Serogroup by race %
Race by serogroup %
Asian/Pacific Islander#
Serogroup by race %
Race by serogroup %
Unknown
#
Serogroup by race %
Race by serogroup %
Total
#
%
Race by serogroup %
§Others=A & W-135

Group
B
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%

Group
C
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%

56

Group Y
1
50%
50%
1
50%
50%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
2
40%
40%

§Others
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%

Groupable
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%

Unknown
1
50%
33%
1
50%
33%
1
100%
33%
0
0%
0%
0
0%
0%
0
0%
0%
3
60%
100%

Total
2
100%
40%
2
100%
40%
1
100%
20%
0
0%
0%
0
0%
0%
0
0%
0%
5
100%

TABLE 7-IMD in MC by Serogroup and Race/Ethnicity
2000-2005
Serogroup
Not
Race/Ethnicity
White
#
Serogroup by race %
Race by serogroup %
Hispanic
#
Serogroup by race %
Race by serogroup %
Black
#
Serogroup by race %
Race by serogroup %
Am Indian/Al Native #
Serogroup by race %
Race by serogroup %
Asian/Pacific Islander#
Serogroup by race %
Race by serogroup %
Unknown
#
Serogroup by race %
Race by serogroup %
Total
#
%
Race by serogroup %
§Others=A & W-135

Group
B
11
20%
38%
14
33%
48%
1
20%
3%
2
67%
7%
0
0%
0%
1
100%
3%
29
27%
100%

Group
C
14
25%
64%
7
17%
32%
1
20%
5%
0
0%
0%
0
0%
0%
0
0%
0%
22
20%
100%

57

Group Y
10
18%
53%
7
17%
37%
2
40%
11%
0
0%
0%
0
0%
0%
0
0%
0%
19
18%
100%

§Others
1
2%
25%
3
7%
75%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
4
4%
100%

Groupable
10
18%
56%
8
19%
44%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
18
17%
100%

Unknown
10
18%
63%
3
7%
19%
1
20%
6%
1
33%
6%
1
100%
6%
0
0%
0%
16
15%
100%

Total
56
100%
52%
42
100%
39%
5
100%
5%
3
100%
3%
1
100%
1%
1
100%
1%
108
100%

H. Invasive Meningococcal Disease (IMD) in Maricopa County(MC) by
Month of Onset, 2000-2006
TABLE 10- IMD in MC by Month of Onset, 1/1/2000-6/30/2006
Month of Onset
January
% of month total
% of year total
February
% of month total
% of year total
March
% of month total
% of year total
April
% of month total
% of year total
May
% of month total
% of year total
June
% of month total
% of year total
July
% of month total
% of year total
August
% of month total
% of year total
September
% of month total
% of year total
October
% of month total
% of year total
November
% of month total
% of year total
December
% of month total
% of year total

2000
6
32%
21%
4
24%
14%
3
17%
11%
1
25%
4%
0
0%
0%
1
17%
4%
1
25%
4%
1
25%
4%
2
100%
7%
4
44%
14%
2
14%
7%
3
33%
11%

2001
1
5%
8%
1
6%
8%
4
22%
31%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
1
25%
8%
0
0%
0%
0
0%
0%
4
29%
31%
2
22%
15%

2002
4
21%
20%
4
24%
20%
4
22%
20%
0
0%
0%
0
0%
0%
2
33%
10%
1
25%
5%
0
0%
0%
0
0%
0%
4
44%
20%
1
7%
5%
0
0%
0%

Year
2003
4
21%
24%
1
6%
6%
2
11%
12%
0
0%
0%
3
43%
18%
0
0%
0%
0
0%
0%
0
0%
0%
0
0%
0%
1
11%
6%
4
29%
24%
2
22%
12%

Total
% of total cases
% of year total

28
25%
100%

13
12%
100%

20
18%
100%

17
15%
100%

11
10%
100%

19
17%
100%

0.90

0.41

0.61

0.50

0.31

0.52

Rate
*Annualized

58

2004
1
5%
9%
1
6%
9%
0
0%
0%
2
50%
18%
1
14%
9%
2
33%
18%
1
25%
9%
2
50%
18%
0
0%
0%
0
0%
0%
1
7%
9%
0
0%
0%

2005
1
5%
5%
4
24%
21%
4
22%
21%
1
25%
5%
3
43%
16%
1
17%
5%
1
25%
5%
0
0%
0%
0
0%
0%
0
0%
0%
2
14%
11%
2
22%
11%

2006
2
11%
40%
2
12%
40%
1
6%
20%
0
0%
0%
0
0%
0%
0
0%
0%

*8

*0.22

Total
19
100%
17%
17
100%
15%
18
100%
16%
4
100%
4%
7
100%
6%
6
100%
5%
4
100%
4%
4
100%
4%
2
100%
2%
9
100%
8%
14
100%
12%
9
100%
8%
113
100%
100%

I. Invasive Meningococcal Disease(IMD) in Maricopa County(MC) by
Serogroup, 2000-2006
TABLE 11-IMD in MC by Serogroup

1/1/2000-6/30/2006

Serogroup
Year
2000
% of year
% of total
2001
% of year
% of total
2002
% of year
% of total
2003
% of year
% of total
2004
% of year
% of total
2005
% of year
% of total
2006
% of year
% of total
Total
% of total

Group B

5
18%
17%
8
62%
28%
10
48%
34%
2
12%
7%
0
0%
0%
4
21%
14%
0
0%
0%
29
26%
100%
§Others=A & W-135

Group C
1
4%
5%
0
0%
0%
6
29%
32%
5
29%
26%
2
18%
11%
5
26%
26%
0
0%
0%
19
17%
100%

Group Y
10
36%
42%
3
23%
13%
2
10%
8%
2
12%
8%
3
27%
13%
2
11%
8%
2
40%
8%
24
21%
100%

59

§Others
2
7%
50%
0
0%
0%
1
5%
25%
0
0%
0%
0
0%
0%
1
5%
25%
0
0%
0%
4
4%
100%

Not
Groupable
7
25%
39%
2
15%
11%
0
0%
0%
6
35%
33%
1
9%
6%
2
11%
11%
0
0%
0%
18
16%
100%

Unknown
3
11%
16%
0
0%
0%
1
5%
5%
2
12%
11%
5
45%
26%
5
26%
26%
3
60%
16%
19
17%
100%

Total
28
100%
25%
13
100%
12%
20
0%
18%
17
100%
15%
11
100%
10%
19
100%
17%
5
100%
4%
113
100%

J. Invasive Meningococcal Disease(IMD) in Maricopa County(MC) Case
Fatality Rates by Syndrome, Race/Ethnicity, Gender, Age, and
Serogroup, 2000-2006

TABLE 12- IMD in MC Case Fatality Rate by Syndrome
1/1/2000-6/30/2006
2000
0%
11%
0%
0%
11%

Syndrome
Meningitis
Bacteremia
Both
Other
Total

2001
0%
0%
0%
0%
0%

2002
10%
5%
10%
0%
24%

Year
2003
0%
6%
0%
0%
6%

2004
0%
0%
0%
0%
0%

2005
0%
5%
0%
0%
5%

2006
20%
20%
0%
0%
40%

Total
3%
6%
2%
0%
11%

TABLE 13- IMD in MC Case Fatality Rate by Race/Ethnicity
1/1/2000-6/30/2006
2000
7%
4%
0%
0%
0%
0%
11%

Race/Ethnicity
White
Hispanic
Black
Am Indian/Alaskan Native
Asian/Pacific Islander
Other
Total

2001
0%
0%
0%
0%
0%
0%
0%

Year
2002
10%
14%
0%
0%
0%
0%
24%

2003
0%
0%
0%
6%
0%
0%
6%

2004
0%
0%
0%
0%
0%
0%
0%

2005
0%
0%
5%
0%
0%
0%
5%

2006
20%
0%
20%
0%
0%
0%
40%

TABLE 14- IMD in MC Case Fatality Rate by Gender
1/1/2000-6/30/2006
Sex
Male
Female
Total

2000
0%
11%
11%

2001
0%
0%
0%

2002
10%
14%
24%

60

Year
2003
0%
6%
6%

2004
0%
0%
0%

2005
5%
0%
5%

2006
20%
20%
40%

Total
4%
7%
11%

Total
4%
4%
2%
1%
0%
0%
11%

TABLE 15- IMD in MC Case Fatality Rate by Age
1/1/2000-6/30/2006
Age
<1 year
1 year
2-4 years
0-4 years
5-9 years
10-13 years
14-17 years
18-24 years
10-24years
25-64 years
65+ years
Total

2000
0%
0%
4%
4%
0%
0%
0%
0%
0%
0%
7%
11%

2001
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%

2002
10%
0%
0%
10%
0%
0%
5%
10%
14%
0%
0%
24%

Year
2003
6%
0%
0%
6%
0%
0%
0%
0%
0%
0%
0%
6%

2004
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%

2005
0%
0%
5%
5%
0%
0%
0%
0%
0%
0%
0%
5%

2006
0%
0%
0%
0%
0%
0%
0%
20%
20%
20%
0%
40%

Total
3%
0%
2%
4%
0%
0%
1%
3%
4%
1%
2%
11%

TABLE 16- IMD in MC Case Fatality Rate by Serogroup
1/1/2000-6/30/2006
Serogroup
Group B
Group C
Group Y
§Others
Not Groupable
Unknown
Total
§Others=A & W-135

2000
0%
0%
7%
4%
0%
0%
11%

2001
0%
0%
0%
0%
0%
0%
0%

61

2002
19%
0%
0%
0%
0%
5%
24%

Year
2003
0%
0%
0%
0%
0%
6%
6%

2004
0%
0%
0%
0%
0%
0%
0%

2005
5%
0%
0%
0%
0%
0%
5%

2006
0%
0%
20%
0%
0%
0%
40%

Total
4%
0%
3%
1%
0%
3%
11%

K. Rate of Invasive Meningococcal Disease(IMD) in the US and
Maricopa County(MC), 1983-2006

TABLE 17-Rate of IMD in the US and MC,
1983-2006
Cases MC
Cases US
Year #
Rate†
#
Rate†
1983
17
1.02
2736
1984
9
0.52
2746
1985
16
0.87
2479
1986
19
1.00
2594
1987
20
1.00
2930
1988
16
0.78
2964
1989
12
0.57
2727
1990
8
0.38
2451
1991
16
0.73
2130
1992
17
0.76
2134
1993
62
2.67
2637
1994
44
1.82
2886
1995
45
1.78
3243
1996
29
1.11
3437
1997
27
1.00
3308
1998
24
0.86
2725
1999
32
1.12
2501
2000
28
0.90
2256
2001
13
0.41
2333
2002
20
0.61
1814
2003
17
0.50
1756
2004
11
0.31
1361
2005
19
0.52
1111
2006
*8
*0.22
N/A
*Annualized
†Population per 100,000, US Census estimates

62

1.17
1.16
1.04
1.08
1.21
1.21
1.10
0.98
0.84
0.84
1.02
1.11
1.23
1.30
1.24
1.01
0.92
0.80
0.82
0.63
0.60
0.46
0.37

L. Population Estimates-Maricopa County(MC)
MC Population Estimates, 2000-2005, by Race/Ethnicity*
Am
Indian/
Al Native
49,461
52,141
53672
55386
57756
60333
328,749

Asian/
Total
White
Hispanic Black
Pac Islander
2000
3,096,692
2,053,712
759,498 110,717
71,067
2001
3,195,893
2,083,248
814,998 115,412
75,360
2002
3,293,441
2113578
868911 120413
79791
2003
3,388,711
2144584
920225 125014
84109
2004
3,498,587
2183362
974637 131052
89519
2005
3,635,528
2235502
1037514 139304
97085
2000-2005 20,108,852 12,813,986 5,375,783 741,912
496,931
†2006
3,778,704
*Source=http://www.census.gov/popest/estimates.php
†Source=MCDPH, Office of Epidemiology
§Combined Group=Black, Am Indian/Al Native, Asian/Pac Islander, and Other

Year

MC Population Estimates, 2000-2005, by Gender*
Year

Total

Male
3,096,692
1,549,174
3,195,893
1,600,713
3,293,441
1651660
3,388,711
1701239
3,498,587
1758613
3,635,528
1829380
†2006
3,778,704
*Source=http://www.census.gov/popest/estimates.php
†Source=MCDPH, Office of Epidemiology
2000
2001
2002
2003
2004
2005

Female
1,547,518
1,595,180
1641781
1687472
1739974
1806148

MC Population Estimates, 2000-2005, by Age*
Year

Total
0-4yrs
5-9 yrs
2000
3,096,692
244,198
239,817
2001
3,195,893
260,208
250,280
2002
3,293,441
270677
257466
2003
3,388,711
280592
262102
2004
3,498,587
290416
268677
2005
3,635,528
298509
275582
2000-2005
20,108,852 1,644,600 1,553,924
†2006
3,778,704
*Source=http://www.census.gov/popest/estimates.php
†Source=MCDPH, Office of Epidemiology

63

10-24yrs
667,692
690,906
710012
726888
745424
767,403
4,308,325

25-64yrs
1,583,864
1,672,191
1,681,776
1,737,305
1,802,134
1,890,981
10,368,251

65+yrs
361,121
367,308
373510
381824
391936
403,053
2,278,752

Other
36,611
38,657
40617
42536
44885
47731
251,037

Combined
Group§
267,856
281,570
294493
307045
323212
344453
1,818,629

MC Population Estimates, 1983-1999*
Year

Total
1983
1,663,973
1984
1,736,952
1985
1,828,748
1986
1,905,504
1987
1,991,400
1988
2,048,441
1989
2,101,787
1990
2,129,352
1991
2,183,182
1992
2,244,827
1993
2,318,774
1994
2,419,394
1995
2,526,113
1996
2,614,093
1997
2,698,459
1998
2,783,779
1999
2,861,395
*Source=http://www.census.gov/popest/estimates.php

64

M. US Population Estimates, 1983-2005
US Population Estimates, 1983-2005*
Year

Total
1983
233,791,994
1984
235,824,902
1985
237,923,795
1986
240,132,887
1987
242,288,918
1988
244,498,982
1989
246,819,230
1990
249,464,396
1991
252,153,092
1992
255,029,699
1993
257,782,608
1994
260,327,021
1995
262,803,276
1996
265,228,572
1997
267,783,607
1998
270,248,003
1999
272,690,813
2000
282,193,477
2001
285,107,923
2002
287,984,799
2003
290,850,005
2004
293,656,842
2005
296,410,404
*Source=http://www.census.gov/popest/estimates.php

65

References
1. Centers for Disease Prevention and Control. Prevention and Control of
Meningococcal Disease: Recommendations of the Advisory Committee on
Immunization Practices (ACIP). MMWR 2005;54(RR-7):1-21
2. Mandell, GL, Bennett, JE, Dolin, R, eds. Principles and Practice of
Infectious Diseases, 6th Edition. Philadelphia, PA: Elsevier; 2005.
3. Maricopa County Department of Public Health(2006). Divisions & Welcome
to the Office of Epidemiology. Available from
http://www.maricopa.gov/Public_Health/ Accessed on 11/19/2006.
4. Maricopa County Department of Public Health, Office of
Epidemiology(2006). Epi Mission Statement Available from MCDPH, Office
of Epidemiology. Obtained 11/17/2006.
5. Baltimore, RS. Recent trends in meningococcal epidemiology and current
vaccine recommendations. Curr Opin Pediatr 18:58-63.
6. Kimmel, SR. Prevention of Meningococcal Disease. American Family
Physician 2005:72(10):2049-2056
7. Centers for Disease Control and Prevention(2006). Meningococcal Disease.
Available from
http://www.cdc.gov/ncidod/DBMD/diseaseinfo/meningococcal_t.htm
Accessed 9/12/2006.
8. Trotter, CL, Gay, NJ, Edmunds, WJ. The natural history of meningococcal
carriage and disease. Epidemiol. Infect. 2005;000:1-11.
9. Gondim, FAA. Meningococcal Meningitis. Available from
http://www.emedicine.com/neuro/topic210.htm Accessed 10/17/2006.
10. Manchanda, V, Gupta, S, Bhalla, P. Meningococcal disease: History,
epidemiology, pathogenesis, clinical manifestations, diagnosis,
antimicrobial susceptibility and prevention. Indian J Med Microbial (serial
online)2006;24:7-19. Available from
http://www.ijm.org/aritcle.asp?issn0255- Accessed 11/2/2006.
11. Gardner, P. Prevention of Meningococcal Disease. N Engl J Med
2006;355(14):1466-73
12. Centers for Disease Control and Prevention(2006). Epidemiology and
Prevention of Vaccine-Preventable Diseases. 9th edition. Meningococcal
Disease. Available from
http://www.cdc.gov/nip/publications/pink/mening.pdf Accessed
11/10/2006.
13. Arizona Department of Health Services(2005). Meningococcal DiseaseQuick Sheet. Available from http://www.adhs.arizona.gov Accessed
8/20/2006
14. Harrison, LH, et.al. Antigenic Shift and Increased Incidence of
Meningococcal disease. JID 2006;193:1266-1274

66

15. Committee on Infectious Diseases. Prevention and Control of
Meningococcal disease: Recommendations for Use of Meningococcal
Vaccines in Pediatric Patients. Pediatrics 2005;16(2):496-505.
16. Pichichero, ME. The new meningococcal conjugate vaccine. Postgraduate
Medicine 2006;119(1). Available from
http://postgradmed.com/isues/2006/06/047/ Accessed 10/22/2006.
17. O’Brien, JA, Caro JJ, Getsios, D. Managing Meningococcal Disease in the
United States: Hospital Case Characteristics and Costs by Age. Value In
Health 2006;9(4):236-243
18. Kaplan, SL, et.al. Multicenter Surveillance of Invasive Meningococcal
Infections in Children. Pediatrics 2006;118(4):e979-e984.
19. Centers for Disease Control and Prevention(2006). Active Bacterial Core
Surveillance (ABCs) Report Emerging Infections Program Network
Neisseria meningitidis, 2000, 2001, 2002, 2003, 2004, 2005-provisional.
Available from http://www.cdc.gov/ncidod/dbmd/abcs/survreports.htm
Accessed 9/12/2006.
20. Centers for Disease Control and Prevention(2006). National Electronic
Telecommunications System for Surveillance. Available from
http://www.cdc.gov/EPO/dphsi/netss.htm Accessed 11/21/2006.
21. Centers for Disease Control and Prevention(2006). Active Bacterial Core
Surveillance. Available from http://www.cdc.gov/ncidod/dbmd/abcs/teamstart.htm Accessed 9/12/2006.
22. Arizona Department of Health Services(2006). Communicable Disease
Reporting. Available from http://www.azdhs.gov/phs/oids/rptlist.htm
Accessed 11/15/2006.
23. Arizona Department of Health Services(2006). Communicable Disease
Case Definitions. Meningococcal Disease. Available from
http://www.azdhs.gov/phs/oids/pdf/casedefinitions_v2006.pdf Accessed
8/20/2006.
24. National Foundation for Infectious Diseases(2004). The Changing

Epidemiology of Meningococcal Disease Among U.S. Children, Adolescents
and Young Adults. Available from

www.nfid.org/pdf/meningitis/FinalChanging_Epidemiology_of_Meningococ
cal_disease.pdf Accessed 11/10/2006.
25. Tappero, JW, et.al. Immunogenicity of 2 Serogroup B Outer-Membrane
Protein Meningococcal Vaccines A Randomized Controlled Trial in Chile.
JAMA 1999;281(16):1520-1527.
26. Tondella, MLC, et.al. Distribution of Neisseria meningitidis Serogroup B
Serosubtypes and Serotypes Circulating in the United States. J Clin
Microbiol 2000;38(9):3323-3328.
27. Rodriguez, AP, Dickinson, F, Baly, A, Martinez, R. The Epidemiological
Impact of Antimeningococcal B Vaccination in Cuba. Mem Inst Oswaldo
Cruz 1999;94(4):433-40.

67

28. Ameratunga, S, et.al. Evaluating the post-licensure effectiveness of a
group B meningococcal vaccine in New Zealand: a multi-faceted strategy.
Vaccine 2005;23:2231-34.
29. Bjune, G, et.al. Effect of outer membrane vesicle vaccine against group B
meningococcal disease in Norway. Lancet 1991;338:1093-96.
30. Noronha, C, Struchiner, CJ, Halloran, ME. Assessment of the Direct
Effectiveness of BC Meningococcal Vaccine in Rio de Janeiro, Brazil: A
Case-Control Study. Int J Epidemiol 1995;24(5):1050-1057.
31. Guiliani, MM, et.al. A universal vaccine for serogroup B meningococcus.
PNAS 2006;103(29):10834-10839.
32. American Academy of Family Physicians(2006). Meningococcal Conjugate
Vaccine: Resume Vaccination of Children Aged 11-12 Years. Available
from
http://www.aafp.org/online/en/home/clinical/immunizationsres/meningoco
ccalvaccine.pri Accessed 11/21/2006.
33. Immunization Action Coalition(2006). Meningococcal Prevention Mandates
for Colleges and Universities. Available from
http://www.immunize.org/laws/menin.htm Accessed 11/11/2006.
34. Dolan-Livengood, JM, et.al. Genetic Basis for Nongroupable Neisseria
meningitidis. JID 2003;187:1616-1628.
35. Centers for Disease Control and Prevention. Summary of notifiable
disease, United States, 2000. MMWR 2000;49(No.53);
2001;50(No.53);2002;51(No.53);2003;52(No.54);2004;53(No.53).
Available from http://www.cdc.gov Accessed 10/15/2006

68